• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

JAMA. Critically Ill Patients With 2009 Influenza A(H1N1) in Mexico

Giuseppe

Giuseppe

Emeritus
Critically Ill Patients With 2009 Influenza A(H1N1) in Mexico, October 12, 2009, Dom?nguez-Cherit et al. 0 (2009): 2009.1536 (JAMA, abstract, edited)
Critically Ill Patients With 2009 Influenza A(H1N1) in Mexico

Guillermo Dom?nguez-Cherit, MD; Stephen E. Lapinsky, MB, BCh, MSc; Alejandro E. Macias, MD; Ruxandra Pinto, PhD(Stat); Lourdes Espinosa-Perez, MD; Alethse de la Torre, MD; Manuel Poblano-Morales, MD; Jose A. Baltazar-Torres, MD; Edgar Bautista, MD; Abril Martinez, MD; Marco A. Martinez, MD; Eduardo Rivero, MD; Rafael Valdez, MD; Guillermo Ruiz-Palacios, MD; Mart?n Hern?ndez, MD; Thomas E. Stewart, MD; Robert A. Fowler, MD, MS(Epi)

JAMA. 2009;302(17): (doi:10.1001/jama.2009.1536).


Context
In March 2009, novel 2009 influenza A(H1N1) was first reported in the southwestern United States and Mexico. The population and health care system in Mexico City experienced the first and greatest early burden of critical illness.

Objective
To describe baseline characteristics, treatment, and outcomes of consecutive critically ill patients in Mexico hospitals that treated the majority of such patients with confirmed, probable, or suspected 2009 influenza A(H1N1).

Design, Setting, and Patients
Observational study of 58 critically ill patients with 2009 influenza A(H1N1) at 6 hospitals between March 24 and June 1, 2009. Demographic data, symptoms, comorbid conditions, illness progression, treatments, and clinical outcomes were collected using a piloted case report form.

Main Outcome Measures
The primary outcome measure was mortality. Secondary outcomes included rate of 2009 influenza (A)H1N1?related critical illness and mechanical ventilation as well as intensive care unit (ICU) and hospital length of stay.

Results
Critical illness occurred in 58 of 899 patients (6.5%) admitted to the hospital with confirmed, probable, or suspected 2009 influenza (A)H1N1. Patients were young (median, 44.0 [range, 10-83] years); all presented with fever and all but 1 with respiratory symptoms. Few patients had comorbid respiratory disorders, but 21 (36%) were obese. Time from hospital to ICU admission was short (median, 1 day [interquartile range {IQR}, 0-3 days]), and all patients but 2 received mechanical ventilation for severe acute respiratory distress syndrome and refractory hypoxemia (median day 1 ratio of PaO2 to fraction of inspired oxygen, 83 [IQR, 59-145] mm Hg). By 60 days, 24 patients had died (41.4%; 95% confidence interval, 28.9%-55.0%). Patients who died had greater initial severity of illness, worse hypoxemia, higher creatine kinase levels, higher creatinine levels, and ongoing organ dysfunction. After adjusting for a reduced opportunity of patients dying early to receive neuraminidase inhibitors, neuraminidase inhibitor treatment (vs no treatment) was associated with improved survival (odds ratio, 7.4; 95% confidence interval, 1.8-31.0).

Conclusion
Critical illness from 2009 influenza A(H1N1) in Mexico occurred in young individuals, was associated with severe acute respiratory distress syndrome and shock, and had a high case-fatality rate.

Author Affiliations:
Division of Pulmonary and Critical Care (Dr Dom?nguez-Cherit), Hospital Epidemiology Department (Drs de la Torre and Macias), Infectious Disease Department (Dr Ruiz-Palacios), and Department of Critical Care Medicine (Dr Rivero), Instituto Nacional de Ciencias M?dicas y Nutrici?n "Salvador Zubir?n," M?xico City, M?xico; Interdepartmental Division of Critical Care Medicine and Department of Medicine, University of Toronto and Mount Sinai Hospital, Toronto, Ontario, Canada (Dr Lapinsky); School of Medicine, Instituto Tecnologico de Estudios Superiores de Monterrey, Monterrey, M?xico (Dr Espinosa-Perez); Interdepartmental Division of Critical Care Medicine and Department of Medicine, University of Toronto and Sunnybrook Health Sciences Centre, Toronto (Dr Pinto); Hospital Juarez de M?xico, M?xico City (Dr Poblano-Morales); Hospital de Especialidades Centro Medico La Raza, IMSS, M?xico City (Dr Baltazar-Torres); Instituto Nacional de Enfermedades Respiratorias, M?xico City (Dr Bautista); Department of Internal Medicine (Drs A. Martinez and M. A. Martinez) and Infectious Disease Hospital (Dr Valdez), Hospital General "Dr. Manuel Gea Gonzalez," M?xico City; Hospital San Jose-Tec de Monterrey, Monterrey City (Dr Hern?ndez); Interdepartmental Division of Critical Care Medicine and Department of Medicine and Anaesthesia, University of Toronto, Mount Sinai Hospital, University Health Network, Toronto (Dr Stewart); and Interdepartmental Division of Critical Care Medicine and Department of Medicine, University of Toronto and Sunnybrook Health Sciences Centre, Toronto (Dr Fowler).
-
​
<cite cite="http://jama.ama-assn.org/cgi/content/abstract/2009.1536v1?etoc">JAMA -- Abstract: Critically Ill Patients With 2009 Influenza A(H1N1) in Mexico, October 12, 2009, Dom?nguez-Cherit et al. 0 (2009): 2009.1536</cite>
 

Attachments

Re: JAMA. Critically Ill Patients With 2009 Influenza A(H1N1) in Mexico

Thank you to JAMA and all the contributors for allowing this paper OPEN ACCESS to the world. Posted in its entirety for our users on dial-up.



[FONT=verdana, arial, helvetica, sans-serif]Critically Ill Patients With 2009 Influenza A(H1N1) in Mexico[/FONT] [FONT=verdana, arial, helvetica, sans-serif] <nobr>Guillermo Domínguez-Cherit, MD</nobr>; <nobr>Stephen E. Lapinsky, MB, BCh, MSc</nobr>; <nobr>Alejandro E. Macias, MD</nobr>; <nobr>Ruxandra Pinto, PhD(Stat)</nobr>; <nobr>Lourdes Espinosa-Perez, MD</nobr>; <nobr>Alethse de la Torre, MD</nobr>; <nobr>Manuel Poblano-Morales, MD</nobr>; <nobr>Jose A. Baltazar-Torres, MD</nobr>; <nobr>Edgar Bautista, MD</nobr>; <nobr>Abril Martinez, MD</nobr>; <nobr>Marco A. Martinez, MD</nobr>; <nobr>Eduardo Rivero, MD</nobr>; <nobr>Rafael Valdez, MD</nobr>; <nobr>Guillermo Ruiz-Palacios, MD</nobr>; <nobr>Martín Hernández, MD</nobr>; <nobr>Thomas E. Stewart, MD</nobr>; <nobr>Robert A. Fowler, MD, MS(Epi)</nobr> [/FONT]

[FONT=verdana, arial, helvetica, sans-serif] JAMA. 2009;302(17)doi:10.1001/jama.2009.1536). [/FONT]
<!-- null --> [FONT=verdana, arial, helvetica, sans-serif] ABSTRACT [/FONT] <table width="100%" border="0" cellpadding="0" cellspacing="0"> <tbody><tr> <td width="100%" bgcolor="#6a90aa">
spacer.gif
</td><td>
spacer.gif
</td></tr></tbody></table>
<!--startindex-->[FONT=verdana, arial, helvetica, sans-serif] Context In March 2009, novel 2009 influenza A(H1N1) was<sup> </sup>first reported in the southwestern United States and Mexico.<sup> </sup>The population and health care system in Mexico City experienced<sup> </sup>the first and greatest early burden of critical illness.<sup> </sup>[/FONT]
[FONT=verdana, arial, helvetica, sans-serif]Objective To describe baseline characteristics, treatment,<sup> </sup>and outcomes of consecutive critically ill patients in Mexico<sup> </sup>hospitals that treated the majority of such patients with confirmed,<sup> </sup>probable, or suspected 2009 influenza A(H1N1).<sup> </sup>[/FONT]
[FONT=verdana, arial, helvetica, sans-serif]Design, Setting, and Patients Observational study of 58<sup> </sup>critically ill patients with 2009 influenza A(H1N1) at 6 hospitals<sup> </sup>between March 24 and June 1, 2009. Demographic data, symptoms,<sup> </sup>comorbid conditions, illness progression, treatments, and clinical<sup> </sup>outcomes were collected using a piloted case report form.<sup> </sup>[/FONT]
[FONT=verdana, arial, helvetica, sans-serif]Main Outcome Measures The primary outcome measure was<sup> </sup>mortality. Secondary outcomes included rate of 2009 influenza<sup> </sup>(A)H1N1–related critical illness and mechanical ventilation<sup> </sup>as well as intensive care unit (ICU) and hospital length of<sup> </sup>stay.<sup> </sup>[/FONT]
[FONT=verdana, arial, helvetica, sans-serif]Results Critical illness occurred in 58 of 899 patients<sup> </sup>(6.5%) admitted to the hospital with confirmed, probable, or<sup> </sup>suspected 2009 influenza (A)H1N1. Patients were young (median,<sup> </sup>44.0 [range, 10-83] years); all presented with fever and all<sup> </sup>but 1 with respiratory symptoms. Few patients had comorbid respiratory<sup> </sup>disorders, but 21 (36%) were obese. Time from hospital to ICU<sup> </sup>admission was short (median, 1 day [interquartile range {IQR},<sup> </sup>0-3 days]), and all patients but 2 received mechanical ventilation<sup> </sup>for severe acute respiratory distress syndrome and refractory<sup> </sup>hypoxemia (median day 1 ratio of Pa[SIZE=-2]O<sub>2</sub> to fraction of inspired<sup> </sup>oxygen, 83 [IQR, 59-145] mm Hg). By 60 days, 24 patients had<sup> </sup>died (41.4%; 95% confidence interval, 28.9%-55.0%). Patients<sup> </sup>who died had greater initial severity of illness, worse hypoxemia,<sup> </sup>higher creatine kinase levels, higher creatinine levels, and<sup> </sup>ongoing organ dysfunction. After adjusting for a reduced opportunity<sup> </sup>of patients dying early to receive neuraminidase inhibitors,<sup> </sup>neuraminidase inhibitor treatment (vs no treatment) was associated<sup> </sup>with improved survival (odds ratio, 7.4; 95% confidence interval,<sup> </sup>1.8-31.0).<sup> </sup>[/SIZE][/FONT]
[FONT=verdana, arial, helvetica, sans-serif]Conclusion Critical illness from 2009 influenza A(H1N1)<sup> </sup>in Mexico occurred in young individuals, was associated with<sup> </sup>severe acute respiratory distress syndrome and shock, and had<sup> </sup>a high case-fatality rate.<sup> </sup>[/FONT]
[FONT=verdana, arial, helvetica, sans-serif]<sup> </sup>[/FONT]

<!--startindex-->[FONT=verdana, arial, helvetica, sans-serif]<!-- null -->
[FONT=verdana, arial, helvetica, sans-serif] INTRODUCTION [/FONT] <table width="100%" border="0" cellpadding="0" cellspacing="0"> <tbody><tr> <td width="100%" bgcolor="#6a90aa">
spacer.gif
</td><td>
spacer.gif
</td></tr></tbody></table> [/FONT] <table marginwidth="0" marginheight="0" leftmargin="0" topmargin="0" align="right" border="0" cellpadding="0" cellspacing="0"> <tbody><tr> <td nowrap="nowrap" valign="top"> <table topmargin="0" leftmargin="0" marginheight="0" marginwidth="0" width="140" border="0" cellpadding="0" cellspacing="0"> <tbody><tr> <td rowspan="2" width="1" align="left" bgcolor="#ffffff">
spacer.gif
</td><td rowspan="2" width="1" align="left" bgcolor="#b1bdbf">
spacer.gif
</td> <td width="138" align="left"> <table valign="top" topmargin="0" leftmargin="0" marginheight="0" marginwidth="0" width="138" align="right" bgcolor="#ffffff" border="0" cellpadding="1" cellspacing="0"> <tbody><tr><td colspan="2" bgcolor="#b1bdbf" height="20" valign="middle">[FONT=verdana,arial,helvetica,sans-serif] Jump to Section[/FONT]</td></tr> <tr><td width="5" valign="TOP"><nobr> •</nobr></td><td valign="top">[FONT=verdana,arial,helvetica,sans-serif]Top[/FONT]</td></tr> <tr><td width="5" valign="TOP"><nobr> •</nobr></td><td valign="top">[FONT=verdana,arial,helvetica,sans-serif]Introduction[/FONT]</td></tr> <tr><td width="5" valign="TOP"><nobr> •</nobr></td><td valign="top">[FONT=verdana,arial,helvetica,sans-serif]Methods[/FONT]</td></tr> <tr><td width="5" valign="TOP"><nobr> •</nobr></td><td valign="top">[FONT=verdana,arial,helvetica,sans-serif]Results[/FONT]</td></tr> <tr><td width="5" valign="TOP"><nobr> •</nobr></td><td valign="top">[FONT=verdana,arial,helvetica,sans-serif]Comment[/FONT]</td></tr> <tr><td width="5" valign="TOP"><nobr> •</nobr></td><td valign="top">[FONT=verdana,arial,helvetica,sans-serif]Author information[/FONT]</td></tr> <tr><td width="5" valign="TOP"><nobr> •</nobr></td><td valign="top">[FONT=verdana,arial,helvetica,sans-serif]References[/FONT]</td></tr> <tr><td colspan="2" height="5">
spacer.gif
</td></tr> </tbody></table></td><td rowspan="2" width="1" align="right" bgcolor="#b1bdbf">
spacer.gif
</td> </tr><tr><td width="138" bgcolor="#b1bdbf" height="1">
spacer.gif
</td> </tr></tbody></table></td></tr></tbody></table> [FONT=verdana, arial, helvetica, sans-serif]
On April 21, 2009, the Centers for Disease Control and Prevention<sup> </sup>reported the detection of 2 cases of human infection with 2009<sup> </sup>influenza A(H1N1) in California.<sup>1</sup> The greatest initial burden<sup> </sup>of critical illness and death occurred in Mexico<sup>2</sup> between March<sup> </sup>18, 2009, and June 1, 2009, with 5029 cases and 97 documented<sup> </sup>deaths.<sup>2-6</sup> By August 30, 2009, there were more than 116 046<sup> </sup>cases with 2234 deaths in the Americas and 277 607 documented<sup> </sup>cases and at least 3205 deaths worldwide.<sup>2, 7</sup><sup> </sup>[/FONT]
[FONT=verdana, arial, helvetica, sans-serif]We report on 58 patients in Mexico who developed critical illness<sup> </sup>from confirmed, probable, or suspected 2009 influenza A(H1N1).<sup> </sup>This early information may be of considerable value for (1)<sup> </sup>the early identification of individuals at risk of becoming<sup> </sup>critically ill and who may benefit from targeted interventions<sup> </sup>including vaccination and antiviral therapy; (2) pandemic health<sup> </sup>care resource planning; and (3) providing baseline 2009 influenza<sup> </sup>A(H1N1)–associated morbidity and mortality data, comparing<sup> </sup>experiences in different jurisdictions, and identifying changes<sup> </sup>in disease virulence over time.<sup> </sup>[/FONT]
[FONT=verdana, arial, helvetica, sans-serif]<!-- null -->
[FONT=verdana, arial, helvetica, sans-serif] METHODS [/FONT] <table width="100%" border="0" cellpadding="0" cellspacing="0"> <tbody><tr> <td width="100%" bgcolor="#6a90aa">
spacer.gif
</td><td>
spacer.gif
</td></tr></tbody></table> [/FONT] <table marginwidth="0" marginheight="0" leftmargin="0" topmargin="0" align="right" border="0" cellpadding="0" cellspacing="0"> <tbody><tr> <td nowrap="nowrap" valign="top"> <table topmargin="0" leftmargin="0" marginheight="0" marginwidth="0" width="140" border="0" cellpadding="0" cellspacing="0"> <tbody><tr> <td rowspan="2" width="1" align="left" bgcolor="#ffffff">
spacer.gif
</td><td rowspan="2" width="1" align="left" bgcolor="#b1bdbf">
spacer.gif
</td> <td width="138" align="left"> <table valign="top" topmargin="0" leftmargin="0" marginheight="0" marginwidth="0" width="138" align="right" bgcolor="#ffffff" border="0" cellpadding="1" cellspacing="0"> <tbody><tr><td colspan="2" bgcolor="#b1bdbf" height="20" valign="middle">[FONT=verdana,arial,helvetica,sans-serif] Jump to Section[/FONT]</td></tr> <tr><td width="5" valign="TOP"><nobr> •</nobr></td><td valign="top">[FONT=verdana,arial,helvetica,sans-serif]Top[/FONT]</td></tr> <tr><td width="5" valign="TOP"><nobr> •</nobr></td><td valign="top">[FONT=verdana,arial,helvetica,sans-serif]Introduction[/FONT]</td></tr> <tr><td width="5" valign="TOP"><nobr> •</nobr></td><td valign="top">[FONT=verdana,arial,helvetica,sans-serif]Methods[/FONT]</td></tr> <tr><td width="5" valign="TOP"><nobr> •</nobr></td><td valign="top">[FONT=verdana,arial,helvetica,sans-serif]Results[/FONT]</td></tr> <tr><td width="5" valign="TOP"><nobr> •</nobr></td><td valign="top">[FONT=verdana,arial,helvetica,sans-serif]Comment[/FONT]</td></tr> <tr><td width="5" valign="TOP"><nobr> •</nobr></td><td valign="top">[FONT=verdana,arial,helvetica,sans-serif]Author information[/FONT]</td></tr> <tr><td width="5" valign="TOP"><nobr> •</nobr></td><td valign="top">[FONT=verdana,arial,helvetica,sans-serif]References[/FONT]</td></tr> <tr><td colspan="2" height="5">
spacer.gif
</td></tr> </tbody></table></td><td rowspan="2" width="1" align="right" bgcolor="#b1bdbf">
spacer.gif
</td> </tr><tr><td width="138" bgcolor="#b1bdbf" height="1">
spacer.gif
</td> </tr></tbody></table></td></tr></tbody></table> [FONT=verdana, arial, helvetica, sans-serif]
[FONT=verdana, arial, helvetica, sans-serif]Study Design[/FONT][/FONT]
[FONT=verdana, arial, helvetica, sans-serif]We retrospectively studied all critically ill patients with<sup> </sup>confirmed, probable, or suspected 2009 influenza A(H1N1) in<sup> </sup>Mexico admitted between March 24, 2009, and June 1, 2009, to<sup> </sup>6 hospitals that were reference centers for the care of patients<sup> </sup>with influenza (Figure 1). Identification of all such patients<sup> </sup>was achieved by examining admission logs for all patient care<sup> </sup>areas, in collaboration with critical care and infectious diseases<sup> </sup>physicians in each participating hospital and with regional<sup> </sup>health authorities in Mexico.<sup> </sup>[/FONT]
[FONT=verdana, arial, helvetica, sans-serif]<!-- null -->
<table width="100%" bgcolor="#6a90aa" border="0" cellpadding="1" cellspacing="0"> <tbody><tr> <td align="center"> <table width="100%" align="center" bgcolor="#6a90aa" border="0" cellpadding="0" cellspacing="0"> <tbody><tr> <td align="left" bgcolor="#dce4ee" valign="top"> <table topmargin="0" leftmargin="0" marginheight="0" marginwidth="0" width="250" border="0" cellpadding="10" cellspacing="0"> <tbody><tr> <td align="center" bgcolor="#dce4ee" valign="center">[FONT=verdana, arial, helvetica, sans-serif]
View larger version (25K):
<nobr>[in this window]
[in a new window]
[as a PowerPoint slide]
</nobr> [/FONT] </td> </tr> </tbody></table> </td> <td width="1" bgcolor="#6a90aa">
spacer.gif
</td> <td width="1000" bgcolor="#ffffff" valign="top"> <table topmargin="0" leftmargin="0" marginheight="0" marginwidth="0" border="0" cellpadding="10" cellspacing="0"> <tbody><tr> <td align="left" bgcolor="#ffffff" valign="top">[FONT=verdana,arial,helvetica,sans-serif] Figure 1. Admissions to Emergency Department, Hospital, and Intensive Care Unit (ICU) in a Single Study Hospital During the 2009 Influenza A(H1N1) Outbreak Period, Mexico, 2009[/FONT] [FONT=verdana,arial,helvetica,sans-serif]Hospitalized patients represent a subset of those assessed in the emergency department; patients admitted to ICU represent a subset of those hospitalized.[/FONT]

</td> </tr> </tbody></table> </td> </tr> </tbody></table> </td> </tr> </tbody></table>
<sup> </sup>[/FONT]
[FONT=verdana, arial, helvetica, sans-serif]We classified patients according to case definitions (confirmed,<sup> </sup>probable, or suspected) developed by the World Health Organization,<sup> </sup>Centers for Disease Control and Prevention, and the National<sup> </sup>Microbiology Laboratory (see eAppendix).<sup>8-10</sup> We defined critically<sup> </sup>ill patients as those admitted to an adult or pediatric intensive<sup> </sup>care unit (ICU); requiring mechanical ventilation; having a<sup> </sup>fraction of inspired oxygen (F[SIZE=-2]IO<sub>2</sub>) greater than or equal to<sup> </sup>60%; or receiving intravenous infusion of inotropic or vasopressor<sup> </sup>medication during the hospitalization.<sup> </sup>[/SIZE][/FONT]
[FONT=verdana, arial, helvetica, sans-serif]To evaluate the proportion of patients who became critically<sup> </sup>ill, we compared our study population with the total number<sup> </sup>of inpatients diagnosed with confirmed, probable, or suspected<sup> </sup>2009 influenza A(H1N1) and treated at any of the participating<sup> </sup>hospitals by June 1, 2009. All patients admitted to these 6<sup> </sup>hospitals with respiratory symptoms or fever were routinely<sup> </sup>screened for 2009 influenza A(H1N1) during the outbreak period.<sup> </sup>[/FONT]
[FONT=verdana, arial, helvetica, sans-serif][FONT=verdana, arial, helvetica, sans-serif]Case Report Generation, Dissemination, and Ethics Approval[/FONT][/FONT]
[FONT=verdana, arial, helvetica, sans-serif]Investigators in Canada collaborated with colleagues in Mexico<sup> </sup>and developed a data collection form with input from critical<sup> </sup>care personnel, infectious diseases clinicians, and clinical<sup> </sup>researchers, including the Canadian Critical Care Trials Group.<sup>11</sup><sup> </sup>Research ethics board review and approval was granted by Sunnybrook<sup> </sup>Health Sciences Centre on April 30, 2009, and subsequently by<sup> </sup>the ethics boards of participating jurisdictions in Mexico.<sup> </sup>The data collection form was posted on academic institutional<sup> </sup>and critical care society Web sites on or after May 3, 2009.<sup>12-14</sup><sup> </sup>Data collection in Mexico commenced on May 1, 2009, was entered<sup> </sup>by study site personnel, transmitted to the coordinating center<sup> </sup>in Toronto, then checked for errors through manual and electronic<sup> </sup>inspection using prespecified range limits.<sup> </sup>[/FONT]
[FONT=verdana, arial, helvetica, sans-serif][FONT=verdana, arial, helvetica, sans-serif]Data Collection[/FONT][/FONT]
[FONT=verdana, arial, helvetica, sans-serif]Data collection included 2009 influenza A(H1N1) and critical<sup> </sup>illness eligibility criteria, demographic data, and details<sup> </sup>of influenza contact, symptoms, comorbid conditions, clinical<sup> </sup>characteristics, time course of the acute illness, microbiology<sup> </sup>samples, and treatments (eAppendix). Severity of illness was<sup> </sup>assessed using the Acute Physiology and Chronic Health Evaluation<sup> </sup>II (APACHE II) score for adults or Pediatric Risk of Mortality<sup> </sup>III score for children.<sup>15-16</sup> Reporting of ventilatory parameters,<sup> </sup>arterial blood gas values, and chest radiograph findings, as<sup> </sup>well as Sequential Organ Failure Assessment (SOFA) scores, was<sup> </sup>performed on days 1, 3, 7, 14, and 28, using the values closest<sup> </sup>to 8:00 [SIZE=-2]AM where appropriate.<sup>17</sup> Outcome variables included duration<sup> </sup>of mechanical ventilation, ICU and hospital length of stay,<sup> </sup>and ICU and hospital mortality at 14, 28, and 60 days from onset<sup> </sup>of critical illness.<sup> </sup>[/SIZE][/FONT]
[FONT=verdana, arial, helvetica, sans-serif]From the largest referral centers, we were able to collect more<sup> </sup>detailed information on the total number of patients presenting<sup> </sup>to the emergency department with influenzalike illness as well<sup> </sup>as those admitted to the hospital and to the ICU, and to calculate<sup> </sup>the proportion of patients critically ill with influenza-related<sup> </sup>pneumonia as a function of total number of ICU beds. In the<sup> </sup>largest centers, we also collected detailed information on health<sup> </sup>care worker exposure and illness to assess risk posed to health<sup> </sup>care professionals through care of patients with 2009 influenza<sup> </sup>A(H1N1).<sup> </sup>[/FONT]
[FONT=verdana, arial, helvetica, sans-serif][FONT=verdana, arial, helvetica, sans-serif]Analysis[/FONT][/FONT]
[FONT=verdana, arial, helvetica, sans-serif]Descriptive data are presented as frequencies (percentages)<sup> </sup>for discrete variables and as means (SDs) or medians (interquartile<sup> </sup>ranges [IQRs]) for continuous variables. Because few patients<sup> </sup>remained alive and in the ICU at 28 days, nonoutcome variables<sup> </sup>are presented on days 1, 3, 7, and 14 but not day 28. To determine<sup> </sup>if there were differences in baseline characteristics between<sup> </sup>patients who survived vs those who died, we used a 2-sample<sup> </sup>t test or the Wilcoxon rank sum test for continuous variables<sup> </sup>and a
khgr.gif
<sup>2</sup> test or Fisher exact test for the discrete variables.<sup> </sup>Analyses to detect differences in treatment variables between<sup> </sup>survivors and nonsurvivors are at risk of confounding due to<sup> </sup>immortal time bias—ie, patients who die quickly have less<sup> </sup>"opportunity" to be exposed to certain therapies. Therefore,<sup> </sup>we restricted comparisons of neuraminidase use to patients who<sup> </sup>did not die within the first 3 days after admission to the hospital<sup> </sup>and adjusted for differences in severity of illness using the<sup> </sup>APACHE II score in a multiple logistic regression model.<sup> </sup>[/FONT]
[FONT=verdana, arial, helvetica, sans-serif]The Kaplan-Meier method was used to determine the probability<sup> </sup>of survival over the duration of follow-up and to generate survival<sup> </sup>curves, censoring at 60 days all individuals discharged from<sup> </sup>the hospital alive. We compared the discriminative ability of<sup> </sup>the day-1 SOFA and APACHE II scores on mortality by testing<sup> </sup>the difference in C statistics (area under the receiver operating<sup> </sup>characteristic curve).<sup> </sup>[/FONT]
[FONT=verdana, arial, helvetica, sans-serif]All statistical tests were 2-tailed, and factors were considered<sup> </sup>statistically significant at
alpha.gif
< .05. SAS version<sup> </sup>9.2 (SAS Institute Inc, Cary, North Carolina) was used for all<sup> </sup>analyses.<sup> </sup>[/FONT]
[FONT=verdana, arial, helvetica, sans-serif]<!-- null -->
[FONT=verdana, arial, helvetica, sans-serif] RESULTS [/FONT] <table width="100%" border="0" cellpadding="0" cellspacing="0"> <tbody><tr> <td width="100%" bgcolor="#6a90aa">
spacer.gif
</td><td>
spacer.gif
</td></tr></tbody></table> [/FONT] <table marginwidth="0" marginheight="0" leftmargin="0" topmargin="0" align="right" border="0" cellpadding="0" cellspacing="0"> <tbody><tr> <td nowrap="nowrap" valign="top"> <table topmargin="0" leftmargin="0" marginheight="0" marginwidth="0" width="140" border="0" cellpadding="0" cellspacing="0"> <tbody><tr> <td rowspan="2" width="1" align="left" bgcolor="#ffffff">
spacer.gif
</td><td rowspan="2" width="1" align="left" bgcolor="#b1bdbf">
spacer.gif
</td> <td width="138" align="left"> <table valign="top" topmargin="0" leftmargin="0" marginheight="0" marginwidth="0" width="138" align="right" bgcolor="#ffffff" border="0" cellpadding="1" cellspacing="0"> <tbody><tr><td colspan="2" bgcolor="#b1bdbf" height="20" valign="middle">[FONT=verdana,arial,helvetica,sans-serif] Jump to Section[/FONT]</td></tr> <tr><td width="5" valign="TOP"><nobr> •</nobr></td><td valign="top">[FONT=verdana,arial,helvetica,sans-serif]Top[/FONT]</td></tr> <tr><td width="5" valign="TOP"><nobr> •</nobr></td><td valign="top">[FONT=verdana,arial,helvetica,sans-serif]Introduction[/FONT]</td></tr> <tr><td width="5" valign="TOP"><nobr> •</nobr></td><td valign="top">[FONT=verdana,arial,helvetica,sans-serif]Methods[/FONT]</td></tr> <tr><td width="5" valign="TOP"><nobr> •</nobr></td><td valign="top">[FONT=verdana,arial,helvetica,sans-serif]Results[/FONT]</td></tr> <tr><td width="5" valign="TOP"><nobr> •</nobr></td><td valign="top">[FONT=verdana,arial,helvetica,sans-serif]Comment[/FONT]</td></tr> <tr><td width="5" valign="TOP"><nobr> •</nobr></td><td valign="top">[FONT=verdana,arial,helvetica,sans-serif]Author information[/FONT]</td></tr> <tr><td width="5" valign="TOP"><nobr> •</nobr></td><td valign="top">[FONT=verdana,arial,helvetica,sans-serif]References[/FONT]</td></tr> <tr><td colspan="2" height="5">
spacer.gif
</td></tr> </tbody></table></td><td rowspan="2" width="1" align="right" bgcolor="#b1bdbf">
spacer.gif
</td> </tr><tr><td width="138" bgcolor="#b1bdbf" height="1">
spacer.gif
</td> </tr></tbody></table></td></tr></tbody></table> [FONT=verdana, arial, helvetica, sans-serif]
[FONT=verdana, arial, helvetica, sans-serif]Characteristics of Study Patients and Hospitals[/FONT][/FONT]
[FONT=verdana, arial, helvetica, sans-serif]During the study period 899 patients with confirmed, probable,<sup> </sup>or suspected 2009 influenza A(H1N1) were assessed and admitted<sup> </sup>to study hospitals having a mean of 289 (SD, 167) beds and 16<sup> </sup>(SD, 8) critical care beds. Critical illness occurred in 58<sup> </sup>patients (6.5%) admitted to the hospital (29 confirmed, 14 probable,<sup> </sup>15 suspected). There were no significant differences in demographics,<sup> </sup>severity of illness, comorbid conditions, or mortality among<sup> </sup>those with confirmed, probable, or suspected 2009 influenza<sup> </sup>A(H1N1), and they are described as a single group.<sup> </sup>[/FONT]
[FONT=verdana, arial, helvetica, sans-serif]As a result of increased patient volumes, many experienced delay<sup> </sup>in admission to the ICU, and 4 remained in the emergency department<sup> </sup>until death. During the period of data collection, there were<sup> </sup>5029 cases of 2009 influenza A(H1N1) and 97 deaths in all of<sup> </sup>Mexico.<sup>18</sup> This cohort from 6 hospitals represents approximately<sup> </sup>one-quarter of all deaths in Mexico during the study period.<sup> </sup>We have described the temporal burden of influenza and H1N1<sup> </sup>on the largest study center, outlining the number of cases of<sup> </sup>influenzalike illness presenting to the emergency department<sup> </sup>and admitted to the hospital and cases of influenza-related<sup> </sup>illness admitted to the ICU (Figure 1). The usual capacity to<sup> </sup>care for critically ill patients was exceeded, necessitating<sup> </sup>care in other patient care areas and the addition of ICU beds<sup> </sup>and ventilators on 2 occasions.<sup> </sup>[/FONT]
[FONT=verdana, arial, helvetica, sans-serif]Study patients were a median age of 44 (range, 10-83) years<sup> </sup>(Figure 2), 53% were female, and 2 were health care workers<sup> </sup>(Table 1). Only 2 children (10 and 14 years) were admitted to<sup> </sup>study centers with critical illness and had mean admission Pediatric<sup> </sup>Risk of Mortality III scores of 6.5 (SD, 2.1). Among all patients,<sup> </sup>symptoms included fever in 58 (100%); respiratory complaints<sup> </sup>(cough, dyspnea, or wheeze) in 57 (98%); generalized weakness<sup> </sup>in 41 (71%); myalgias in 35 (60%); headache in 33 (57%); and<sup> </sup>gastrointestinal symptoms of nausea, vomiting, or diarrhea in<sup> </sup>18 (30%).<sup> </sup>[/FONT]
[FONT=verdana, arial, helvetica, sans-serif]<!-- null -->
<table width="100%" bgcolor="#6a90aa" border="0" cellpadding="1" cellspacing="0"> <tbody><tr> <td align="center"> <table width="100%" align="center" bgcolor="#6a90aa" border="0" cellpadding="0" cellspacing="0"> <tbody><tr> <td align="left" bgcolor="#dce4ee" valign="top"> <table topmargin="0" leftmargin="0" marginheight="0" marginwidth="0" width="250" border="0" cellpadding="10" cellspacing="0"> <tbody><tr> <td align="center" bgcolor="#dce4ee" valign="center">[FONT=verdana, arial, helvetica, sans-serif]
View larger version (17K):
<nobr>[in this window]
[in a new window]
[as a PowerPoint slide]
</nobr> [/FONT] </td> </tr> </tbody></table> </td> <td width="1" bgcolor="#6a90aa">
spacer.gif
</td> <td width="1000" bgcolor="#ffffff" valign="top"> <table topmargin="0" leftmargin="0" marginheight="0" marginwidth="0" border="0" cellpadding="10" cellspacing="0"> <tbody><tr> <td align="left" bgcolor="#ffffff" valign="top">[FONT=verdana,arial,helvetica,sans-serif] Figure 2. Age Distribution of 58 Critically Ill Patients With Confirmed, Probable, or Suspected 2009 Influenza A(H1N1) Infection[/FONT] [FONT=verdana,arial,helvetica,sans-serif]Intervals on the x-axis are equal to the lower limit and less than the upper limit.[/FONT]

</td> </tr> </tbody></table> </td> </tr> </tbody></table> </td> </tr> </tbody></table>
<!-- null -->
<table width="100%" bgcolor="#6a90aa" border="0" cellpadding="1" cellspacing="0"> <tbody><tr> <td align="center"> <table width="100%" align="center" bgcolor="#6a90aa" border="0" cellpadding="0" cellspacing="0"> <tbody><tr> <td align="left" bgcolor="#dce4ee" valign="top"> <table topmargin="0" leftmargin="0" marginheight="0" marginwidth="0" width="140" border="0" cellpadding="10" cellspacing="0"> <tbody><tr> <td align="center" bgcolor="#dce4ee" valign="center">[FONT=verdana, arial, helvetica, sans-serif] View this table:
<nobr>[in this window]
[in a new window]
[as a PowerPoint slide]
</nobr> [/FONT] </td> </tr> </tbody></table> </td> <td width="1" bgcolor="#6a90aa">
spacer.gif
</td> <td width="1000" bgcolor="#ffffff" valign="top"> <table topmargin="0" leftmargin="0" marginheight="0" marginwidth="0" border="0" cellpadding="10" cellspacing="0"> <tbody><tr> <td align="left" bgcolor="#ffffff" valign="top">[FONT=verdana,arial,helvetica,sans-serif] Table 1. Characteristics of Critically Ill Patients With Confirmed, Probable, or Suspected 2009 Influenza A(H1N1) Infection, March 24, 2009, to June 1, 2009[/FONT]
</td> </tr> </tbody></table> </td> </tr> </tbody></table> </td> </tr> </tbody></table>
<sup> </sup>[/FONT]
[FONT=verdana, arial, helvetica, sans-serif]<sup> </sup>[/FONT]
[FONT=verdana, arial, helvetica, sans-serif]The median number of comorbid conditions was 2 (IQR, 1-4) (Table 1).<sup> </sup>Only 2 patients had a history of chronic obstructive pulmonary<sup> </sup>disease. Obesity was the most common comorbid condition (mean<sup> </sup>body mass index [BMI], 32 [SD, 12], calculated as weight in<sup> </sup>kilograms divided by height in meters squared). Twenty-one patients<sup> </sup>(36%) had a BMI greater than 30; 8 (14%) were morbidly obese<sup> </sup>(BMI >40).<sup> </sup>[/FONT]
[FONT=verdana, arial, helvetica, sans-serif][FONT=verdana, arial, helvetica, sans-serif]Course of Illness and Treatments Received[/FONT][/FONT]
[FONT=verdana, arial, helvetica, sans-serif]Medical Therapies. Patients developed first symptoms a median<sup> </sup>of 6 (IQR, 4-8) days prior to hospitalization. Time from hospitalization<sup> </sup>to ICU admission was 1 (IQR, 0-3) day. Among 55 patients confirmed<sup> </sup>to have received medical therapies (unknown for 3), 52 (95%)<sup> </sup>were treated with antibiotics, while 45 (78%) received neuraminidase<sup> </sup>inhibitors (oseltamivir [44], zanamivir [6]), 8 received amantidine<sup> </sup>(14%), 1 rimantidine (2%), and 40 (69%) corticosteroids. Two<sup> </sup>patients received recombinant activated protein C. Two had received<sup> </sup>an influenza vaccination in 2008 or 2009.<sup> </sup>[/FONT]
[FONT=verdana, arial, helvetica, sans-serif]Ventilation Support. Fifty-four patients, including 1 of 2 children,<sup> </sup>required mechanical ventilation (48 invasive, 22 noninvasive,<sup> </sup>16 both) during the course of hospitalization (Table 2 and eTable).<sup>19</sup><sup> </sup>On the first day of critical illness, the mean F[SIZE=-2]IO<sub>2</sub> was 72%<sup> </sup>(SD, 26%), set positive end-expiratory pressure (PEEP) was 13<sup> </sup>(SD, 5) cm H<sub>2</sub>O, and plateau pressure was 27 (SD, 7) cm H<sub>2</sub>O.<sup> </sup>Median ratio of Pa[SIZE=-2]O[/SIZE]<sub>2</sub> to F[SIZE=-2]IO[/SIZE]<sub>2</sub> was 83 (IQR, 59-145) mm Hg, with<sup> </sup>oxygen saturation of 88% (SD, 13%). Four patients received prone<sup> </sup>ventilation on their first day in the ICU, owing to severe hypoxia.<sup> </sup>Tidal volume per ideal body weight was 8.3 (SD, 3) mL/kg. Day<sup> </sup>1 chest radiographs demonstrated bilateral disease in 95.6%<sup> </sup>of patients. Barotrauma occurred in 6 patients (10.3%) over<sup> </sup>the study. Patients received high F[SIZE=-2]IO[/SIZE]<sub>2</sub>, high PEEP, and were<sup> </sup>commonly ventilated in the prone position. Only 1 patient received<sup> </sup>high-frequency oscillatory ventilation, and none was known to<sup> </sup>receive nitric oxide or extracorporeal membrane oxygenation.<sup> </sup>[/SIZE][/FONT]
[FONT=verdana, arial, helvetica, sans-serif]<!-- null -->
<table width="100%" bgcolor="#6a90aa" border="0" cellpadding="1" cellspacing="0"> <tbody><tr> <td align="center"> <table width="100%" align="center" bgcolor="#6a90aa" border="0" cellpadding="0" cellspacing="0"> <tbody><tr> <td align="left" bgcolor="#dce4ee" valign="top"> <table topmargin="0" leftmargin="0" marginheight="0" marginwidth="0" width="140" border="0" cellpadding="10" cellspacing="0"> <tbody><tr> <td align="center" bgcolor="#dce4ee" valign="center">[FONT=verdana, arial, helvetica, sans-serif] View this table:
<nobr>[in this window]
[in a new window]
[as a PowerPoint slide]
</nobr> [/FONT] </td> </tr> </tbody></table> </td> <td width="1" bgcolor="#6a90aa">
spacer.gif
</td> <td width="1000" bgcolor="#ffffff" valign="top"> <table topmargin="0" leftmargin="0" marginheight="0" marginwidth="0" border="0" cellpadding="10" cellspacing="0"> <tbody><tr> <td align="left" bgcolor="#ffffff" valign="top">[FONT=verdana,arial,helvetica,sans-serif] Table 2. Organ Dysfunction Over Time Among 58 Critically Ill Patients With Confirmed, Probable, or Suspected 2009 Influenza A(H1N1) Infection<sup>a</sup>[/FONT]
</td> </tr> </tbody></table> </td> </tr> </tbody></table> </td> </tr> </tbody></table>
<sup> </sup>[/FONT]
[FONT=verdana, arial, helvetica, sans-serif]Nonrespiratory Organ Dysfunction. A large number of patients<sup> </sup>(34 [58.6%]) initially required inotropic or vasoactive medications<sup> </sup>at day 1 (Table 2). Creatine kinase level was elevated (285<sup> </sup>[IQR, 136-1159] IU/L). Initial other organ dysfunction was mild.<sup> </sup>Over the course of follow-up, hypotension requiring vasoactive<sup> </sup>medication support remained common at days 3, 7, and 14. Staphylococcus<sup> </sup>aureus was the most commonly identified cause of secondary bacterial<sup> </sup>pneumonia (4 patients).<sup> </sup>[/FONT]
[FONT=verdana, arial, helvetica, sans-serif]Outcomes. After 60 days from the onset of critical illness,<sup> </sup>24 of 58 patients (41.4%; 95% confidence interval [CI], 28.9%-55.0%)<sup> </sup>had died (Table 3, Figure 3). In Mexico, most (19) patients<sup> </sup>died within the first 2 weeks after becoming critically ill.<sup> </sup>An additional 4 patients died by day 28, with only 1 additional<sup> </sup>death occurring within 60 days.<sup> </sup>[/FONT]
[FONT=verdana, arial, helvetica, sans-serif]<!-- null -->
<table width="100%" bgcolor="#6a90aa" border="0" cellpadding="1" cellspacing="0"> <tbody><tr> <td align="center"> <table width="100%" align="center" bgcolor="#6a90aa" border="0" cellpadding="0" cellspacing="0"> <tbody><tr> <td align="left" bgcolor="#dce4ee" valign="top"> <table topmargin="0" leftmargin="0" marginheight="0" marginwidth="0" width="140" border="0" cellpadding="10" cellspacing="0"> <tbody><tr> <td align="center" bgcolor="#dce4ee" valign="center">[FONT=verdana, arial, helvetica, sans-serif] View this table:
<nobr>[in this window]
[in a new window]
[as a PowerPoint slide]
</nobr> [/FONT] </td> </tr> </tbody></table> </td> <td width="1" bgcolor="#6a90aa">
spacer.gif
</td> <td width="1000" bgcolor="#ffffff" valign="top"> <table topmargin="0" leftmargin="0" marginheight="0" marginwidth="0" border="0" cellpadding="10" cellspacing="0"> <tbody><tr> <td align="left" bgcolor="#ffffff" valign="top">[FONT=verdana,arial,helvetica,sans-serif] Table 3. Clinical Course and Outcomes of Patients With Confirmed, Probable, or Suspected 2009 Influenza A(H1N1) Infection[/FONT]
</td> </tr> </tbody></table> </td> </tr> </tbody></table> </td> </tr> </tbody></table>
<!-- null -->
<table width="100%" bgcolor="#6a90aa" border="0" cellpadding="1" cellspacing="0"> <tbody><tr> <td align="center"> <table width="100%" align="center" bgcolor="#6a90aa" border="0" cellpadding="0" cellspacing="0"> <tbody><tr> <td align="left" bgcolor="#dce4ee" valign="top"> <table topmargin="0" leftmargin="0" marginheight="0" marginwidth="0" width="250" border="0" cellpadding="10" cellspacing="0"> <tbody><tr> <td align="center" bgcolor="#dce4ee" valign="center">[FONT=verdana, arial, helvetica, sans-serif]
View larger version (23K):
<nobr>[in this window]
[in a new window]
[as a PowerPoint slide]
</nobr> [/FONT] </td> </tr> </tbody></table> </td> <td width="1" bgcolor="#6a90aa">
spacer.gif
</td> <td width="1000" bgcolor="#ffffff" valign="top"> <table topmargin="0" leftmargin="0" marginheight="0" marginwidth="0" border="0" cellpadding="10" cellspacing="0"> <tbody><tr> <td align="left" bgcolor="#ffffff" valign="top">[FONT=verdana,arial,helvetica,sans-serif] Figure 3. Survival of Patients Critically Ill With Confirmed, Probable, or Suspected 2009 Influenza A(H1N1) Infection[/FONT] [FONT=verdana,arial,helvetica,sans-serif]Dashed lines indicate 95% confidence intervals.[/FONT]

</td> </tr> </tbody></table> </td> </tr> </tbody></table> </td> </tr> </tbody></table>
<sup> </sup>[/FONT]
[FONT=verdana, arial, helvetica, sans-serif]<sup> </sup>[/FONT]
[FONT=verdana, arial, helvetica, sans-serif]Four patients died in the emergency department, 3 within 8 hours<sup> </sup>and 1 within 24 hours of arrival. All deaths within 28 days<sup> </sup>were primarily related to respiratory failure, with only 1 late<sup> </sup>death primarily related to multisystem organ dysfunction. The<sup> </sup>2 included children both survived and were discharged from the<sup> </sup>hospital. Intensive care unit length of stay among survivors<sup> </sup>was 13.5 (IQR, 6-24) days, while nonsurvivors died 7.0 (IQR,<sup> </sup>2-13) days after ICU admission (Table 3). Duration of mechanical<sup> </sup>ventilation among survivors was 15 (IQR, 8-26) days and among<sup> </sup>nonsurvivors was 7.5 (IQR, 3-13.5) days. Many patients received<sup> </sup>ventilation outside of the ICU.<sup> </sup>[/FONT]
[FONT=verdana, arial, helvetica, sans-serif]Comparison of Survivors and Nonsurvivors. Patients who died<sup> </sup>were more likely to have a higher APACHE II and SOFA score,<sup> </sup>lower mean arterial pressure at admission, evidence of renal<sup> </sup>and hepatic organ injury, lower ratio of Pa[SIZE=-2]O<sub>2</sub> to F[SIZE=-2]IO[/SIZE]<sub>2</sub>, and higher<sup> </sup>set PEEP at admission to the ICU (Table 4). There were no significant<sup> </sup>differences in tidal volume or ventilation strategies between<sup> </sup>survivors and nonsurvivors. Patients with higher creatine kinase<sup> </sup>levels had a greater likelihood of dying at 28 days. Both APACHE<sup> </sup>II and day-1 SOFA score were significantly associated with 28-day<sup> </sup>mortality (P < .001 for both), and there was no<sup> </sup>difference in predictive value (C = 0.83 and C = 0.87,<sup> </sup>respectively; P = .52). After excluding patients dying<sup> </sup>early (within 72 hours of illness onset), who may have had less<sup> </sup>opportunity to be exposed to neuraminidase inhibitors, survivors<sup> </sup>were more likely to have received treatment with neuraminidase<sup> </sup>inhibitors (odds ratio, 7.4; 95% CI, 1.8-31.0; P = .006).<sup> </sup>[/SIZE][/FONT]
[FONT=verdana, arial, helvetica, sans-serif]<!-- null -->
<table width="100%" bgcolor="#6a90aa" border="0" cellpadding="1" cellspacing="0"> <tbody><tr> <td align="center"> <table width="100%" align="center" bgcolor="#6a90aa" border="0" cellpadding="0" cellspacing="0"> <tbody><tr> <td align="left" bgcolor="#dce4ee" valign="top"> <table topmargin="0" leftmargin="0" marginheight="0" marginwidth="0" width="140" border="0" cellpadding="10" cellspacing="0"> <tbody><tr> <td align="center" bgcolor="#dce4ee" valign="center">[FONT=verdana, arial, helvetica, sans-serif] View this table:
<nobr>[in this window]
[in a new window]
[as a PowerPoint slide]
</nobr> [/FONT] </td> </tr> </tbody></table> </td> <td width="1" bgcolor="#6a90aa">
spacer.gif
</td> <td width="1000" bgcolor="#ffffff" valign="top"> <table topmargin="0" leftmargin="0" marginheight="0" marginwidth="0" border="0" cellpadding="10" cellspacing="0"> <tbody><tr> <td align="left" bgcolor="#ffffff" valign="top">[FONT=verdana,arial,helvetica,sans-serif] Table 4. Comparison of Survivors and Nonsurvivors[/FONT]
</td> </tr> </tbody></table> </td> </tr> </tbody></table> </td> </tr> </tbody></table>
<sup> </sup>[/FONT]
[FONT=verdana, arial, helvetica, sans-serif]Risk to Health Care Workers. Among the 3 largest centers caring<sup> </sup>for 65.6% of the patients in this series, 40 of 6755 health<sup> </sup>care workers (0.6%) developed 2009 influenza A(H1N1), including<sup> </sup>10 of 2421 workers (0.5%) from clinical areas. Only 1 health<sup> </sup>care worker became critically ill, and this patient was believed<sup> </sup>to have acquired H1N1 outside of the workplace.<sup> </sup>[/FONT]
[FONT=verdana, arial, helvetica, sans-serif]<!-- null -->
[FONT=verdana, arial, helvetica, sans-serif] COMMENT [/FONT] <table width="100%" border="0" cellpadding="0" cellspacing="0"> <tbody><tr> <td width="100%" bgcolor="#6a90aa">
spacer.gif
</td><td>
spacer.gif
</td></tr></tbody></table> [/FONT] <table marginwidth="0" marginheight="0" leftmargin="0" topmargin="0" align="right" border="0" cellpadding="0" cellspacing="0"> <tbody><tr> <td nowrap="nowrap" valign="top"> <table topmargin="0" leftmargin="0" marginheight="0" marginwidth="0" width="140" border="0" cellpadding="0" cellspacing="0"> <tbody><tr> <td rowspan="2" width="1" align="left" bgcolor="#ffffff">
spacer.gif
</td><td rowspan="2" width="1" align="left" bgcolor="#b1bdbf">
spacer.gif
</td> <td width="138" align="left"> <table valign="top" topmargin="0" leftmargin="0" marginheight="0" marginwidth="0" width="138" align="right" bgcolor="#ffffff" border="0" cellpadding="1" cellspacing="0"> <tbody><tr><td colspan="2" bgcolor="#b1bdbf" height="20" valign="middle">[FONT=verdana,arial,helvetica,sans-serif] Jump to Section[/FONT]</td></tr> <tr><td width="5" valign="TOP"><nobr> •</nobr></td><td valign="top">[FONT=verdana,arial,helvetica,sans-serif]Top[/FONT]</td></tr> <tr><td width="5" valign="TOP"><nobr> •</nobr></td><td valign="top">[FONT=verdana,arial,helvetica,sans-serif]Introduction[/FONT]</td></tr> <tr><td width="5" valign="TOP"><nobr> •</nobr></td><td valign="top">[FONT=verdana,arial,helvetica,sans-serif]Methods[/FONT]</td></tr> <tr><td width="5" valign="TOP"><nobr> •</nobr></td><td valign="top">[FONT=verdana,arial,helvetica,sans-serif]Results[/FONT]</td></tr> <tr><td width="5" valign="TOP"><nobr> •</nobr></td><td valign="top">[FONT=verdana,arial,helvetica,sans-serif]Comment[/FONT]</td></tr> <tr><td width="5" valign="TOP"><nobr> •</nobr></td><td valign="top">[FONT=verdana,arial,helvetica,sans-serif]Author information[/FONT]</td></tr> <tr><td width="5" valign="TOP"><nobr> •</nobr></td><td valign="top">[FONT=verdana,arial,helvetica,sans-serif]References[/FONT]</td></tr> <tr><td colspan="2" height="5">
spacer.gif
</td></tr> </tbody></table></td><td rowspan="2" width="1" align="right" bgcolor="#b1bdbf">
spacer.gif
</td> </tr><tr><td width="138" bgcolor="#b1bdbf" height="1">
spacer.gif
</td> </tr></tbody></table></td></tr></tbody></table> [FONT=verdana, arial, helvetica, sans-serif]
Our analysis of critically ill patients with 2009 influenza<sup> </sup>A(H1N1) reveals that this disease affected a young patient group.<sup> </sup>Fever and respiratory symptoms were harbingers of disease in<sup> </sup>almost all cases. There was a relatively long period of illness<sup> </sup>prior to presentation to the hospital, followed by a short period<sup> </sup>of acute and severe respiratory deterioration. These patients<sup> </sup>had severe hypoxia and acute respiratory distress syndrome and<sup> </sup>required high F[SIZE=-2]IO<sub>2</sub>, PEEP, and ventilatory pressures. Within<sup> </sup>60 days, 41% of critically ill patients had died.<sup> </sup>[/SIZE][/FONT]
[FONT=verdana, arial, helvetica, sans-serif]The mortality rate of 41% for 2009 influenza A(H1N1)–associated<sup> </sup>critical illness is not dissimilar to that for acute respiratory<sup> </sup>distress syndrome resulting from other influenza but is higher<sup> </sup>than that for severe acute respiratory syndrome (SARS), and<sup> </sup>deaths in Mexico appear to have been more directly related to<sup> </sup>respiratory rather than multiorgan failure.<sup>20-22</sup> The low median<sup> </sup>age and relatively good prior health of this critically ill<sup> </sup>group are different from those for seasonal influenza and SARS,<sup>22</sup><sup> </sup>in which older patients appear more susceptible to severe disease.<sup> </sup>[/FONT]
[FONT=verdana, arial, helvetica, sans-serif]Although serologic studies suggest that 2009 influenza A(H1N1)<sup> </sup>is a novel influenza strain with little protection afforded<sup> </sup>by seasonal influenza vaccination, adults older than 60 years<sup> </sup>appear to have some preexisting immunity to this novel virus.<sup>23</sup><sup> </sup>While a degree of cross-immunity might be afforded through a<sup> </sup>long history of annual vaccination, the specific effect of uncommon<sup> </sup>prior seasonal influenza vaccination, if any, is unclear. The<sup> </sup>age distribution of the general population in Mexico differs<sup> </sup>from that in many developed nations, with a much larger proportion<sup> </sup>of the population in lower age categories, and therefore it<sup> </sup>may not be surprising that young individuals comprise a greater<sup> </sup>proportion of those infected.<sup>24</sup><sup> </sup>[/FONT]
[FONT=verdana, arial, helvetica, sans-serif]Approximately 18% of critically ill patients with SARS were<sup> </sup>health care workers.<sup>22</sup> With SARS, viral shedding appeared to<sup> </sup>peak at about 7 days, coinciding with the time of ICU admission<sup> </sup>for many patients. Viral shedding in seasonal influenza is maximal<sup> </sup>near onset of the disease, then decreases rapidly.<sup>25</sup> These patients<sup> </sup>presented to the hospital and were admitted to the ICU a median<sup> </sup>of 6 days after disease onset, which may in part explain the<sup> </sup>apparent lack of nosocomial transmission among critically ill<sup> </sup>patients. Avian influenza A(H5N1) outbreaks would appear to<sup> </sup>have a significantly higher mortality than 2009 influenza A(H1N1)<sup> </sup>in patients requiring advanced organ support (approximately<sup> </sup>90%, with median time from hospital admission to death of 6<sup> </sup>days).<sup>26-28</sup> These baseline data will allow evaluation of whether<sup> </sup>the morbidity and mortality of this infection are worsening<sup> </sup>over time, which has been the case in many other pandemics.<sup>29</sup><sup> </sup>[/FONT]
[FONT=verdana, arial, helvetica, sans-serif]We found that certain baseline characteristics of critically<sup> </sup>ill patients with 2009 influenza A(H1N1) may be associated with<sup> </sup>increased mortality, including cardiovascular, respiratory,<sup> </sup>and renal organ dysfunction. Novel findings include possible<sup> </sup>worse outcomes among patients presenting with an elevated creatine<sup> </sup>kinase level. Elevated creatine kinase levels and rhabdomyolysis<sup> </sup>have been previously reported to complicate seasonal influenza,<sup> </sup>although more commonly in children.<sup>30-31</sup> Obesity was the most<sup> </sup>common comorbid condition in these patients and was more prevalent<sup> </sup>(36%) in this series than the general population prevalence<sup> </sup>(30%) in Mexico.<sup>32</sup> However, mortality was not significantly<sup> </sup>higher among obese patients compared with nonobese patients.<sup> </sup>Among other patient cohorts with undifferentiated acute respiratory<sup> </sup>distress syndrome, increased BMI has not emerged as a predictor<sup> </sup>of mortality.<sup>33</sup><sup> </sup>[/FONT]
[FONT=verdana, arial, helvetica, sans-serif]A better understanding of these factors, which were common,<sup> </sup>or those that suggest a higher mortality may provide health<sup> </sup>care professionals an earlier opportunity to identify and treat<sup> </sup>high-risk groups. Importantly, we found in this cohort that<sup> </sup>either SOFA or APACHE II scores may help to identify patients<sup> </sup>at high risk of death. Some authors have previously suggested<sup> </sup>the use of SOFA scores for triage during pandemic periods, owing<sup> </sup>to their relative ease of calculation.<sup>34</sup><sup> </sup>[/FONT]
[FONT=verdana, arial, helvetica, sans-serif]The strengths of this study include a large and detailed description<sup> </sup>of patients critically ill as a result of 2009 influenza A(H1N1).<sup> </sup>We have highlighted what appear to be differences in severity<sup> </sup>of illness, associations, and outcomes from other recent infectious<sup> </sup>respiratory outbreaks. The methods of rapid case report modification,<sup> </sup>research ethics approval, international dissemination, and analysis<sup> </sup>provide a potential example for future outbreak characterization<sup>11</sup><sup> </sup>and potential for international comparisons among countries<sup> </sup>with different health care systems and capacity for care.<sup> </sup>[/FONT]
[FONT=verdana, arial, helvetica, sans-serif]This study has several potential limitations. First, it represents<sup> </sup>a relatively early examination of the epidemiology of a severe<sup> </sup>infectious disease. Early reports risk overestimating the case-fatality<sup> </sup>rate through selective recognition and screening of the most<sup> </sup>severely ill patients. This may partially explain a high mortality<sup> </sup>in Mexico early in the outbreak; however, our cohort included<sup> </sup>all patients hospitalized with critical illness, not only those<sup> </sup>selected for admission to an ICU, thus minimizing the effect<sup> </sup>of selective triaging of critically ill patients (by age, comorbidity,<sup> </sup>etc) and minimizing the potential for overrepresentation of<sup> </sup>patients with certain characteristics or severity of illness.<sup> </sup>Also, the 6 hospitals participating in this cohort study had<sup> </sup>specific criteria for 2009 influenza A(H1N1) screening among<sup> </sup>all hospitalized patients, minimizing the risk of exposure ascertainment<sup> </sup>bias through overestimation of disease among only the sickest<sup> </sup>patients. For this early report, we deliberately included suspected,<sup> </sup>in addition to confirmed and probable, cases of 2009 influenza<sup> </sup>A(H1N1) because in the earliest stages of the outbreak, confirmatory<sup> </sup>testing was sometimes unavailable for patients who died rapidly<sup> </sup>and in settings with resources that did not initially permit<sup> </sup>testing. We performed all analyses in duplicate and found no<sup> </sup>significant differences in outcomes when including only confirmed<sup> </sup>and probable cases.<sup> </sup>[/FONT]
[FONT=verdana, arial, helvetica, sans-serif]It is possible that the 2009 influenza A(H1N1) experience described<sup> </sup>here is somewhat unique to Mexico and may be related to a variety<sup> </sup>of factors, including climate, air quality, and altitude (2240<sup> </sup>m above sea level) in Mexico City; or, noting the long duration<sup> </sup>between illness onset and presentation to the hospital with<sup> </sup>severe disease, potential differences in the timing of access<sup> </sup>or presentation of the population to acute care compared with<sup> </sup>other settings. These critically ill patients presented to the<sup> </sup>hospital already very ill. Four patients died before admission<sup> </sup>to the ICU, 3 of these within 8 hours of presentation to the<sup> </sup>hospital. Despite these potential differences with other recently<sup> </sup>characterized outbreaks, the experience in Mexico may well represent<sup> </sup>a global "median" of illness presentation and outcome for 2009<sup> </sup>influenza A(H1N1) more appropriate than reports only from the<sup> </sup>most well-resourced health care settings.<sup>22</sup><sup> </sup>[/FONT]
[FONT=verdana, arial, helvetica, sans-serif]As of August 30, 2009, the World Health Organization reported<sup> </sup>254 206 cases of 2009 influenza A(H1N1) and 2837 deaths,<sup> </sup>for a case-fatality rate of approximately 1%—yet this<sup> </sup>may well be an overestimate, because testing is no longer being<sup> </sup>reported in many jurisdictions.<sup>2</sup> The case-fatality rate in previous<sup> </sup>influenza pandemics has varied widely, and all such reports<sup> </sup>may be inaccurate owing to difficulty in assessing the denominator<sup> </sup>(ie, the total number of cases).<sup>35</sup> The Spanish flu of 1918 is<sup> </sup>reported as causing 50 million deaths in 500 million individuals<sup> </sup>infected (10% case-fatality rate), while the Hong Kong flu of<sup> </sup>1968-1969 caused 33 000 deaths among 50 million infected<sup> </sup>(<0.1% case-fatality rate).<sup>36</sup> The case-fatality rate of avian<sup> </sup>influenza A(H5N1) was initially reported to be as high as 60%<sup> </sup>but is more likely in the range of 14% to 33%.<sup>28</sup><sup> </sup>[/FONT]
[FONT=verdana, arial, helvetica, sans-serif]From the Mexico experience, it is clear that in certain environments,<sup> </sup>critical illness from 2009 influenza A(H1N1) may be associated<sup> </sup>with severe acute lung injury, refractory hypoxia, and a high<sup> </sup>mortality rate in young individuals. Influenza pandemics of<sup> </sup>the past century have been associated with a remarkably consistent<sup> </sup>epidemiologic curve, with peaks in the spring, fall, and later<sup> </sup>winter.<sup>7</sup> Early recognition of disease by the consistent symptoms<sup> </sup>of fever and a respiratory illness during times of outbreak,<sup> </sup>with prompt medical attention including neuraminidase inhibitors<sup> </sup>and aggressive support of oxygenation failure and subsequent<sup> </sup>organ dysfunction, may provide opportunities to mitigate the<sup> </sup>progression of illness and mortality observed in Mexico.<sup> </sup>[/FONT]
[FONT=verdana, arial, helvetica, sans-serif]<!-- null --> <!-- null -->
[FONT=verdana, arial, helvetica, sans-serif] AUTHOR INFORMATION [/FONT] <table width="100%" border="0" cellpadding="0" cellspacing="0"> <tbody><tr> <td width="100%" bgcolor="#6a90aa">
spacer.gif
</td><td>
spacer.gif
</td></tr></tbody></table> [/FONT] <table marginwidth="0" marginheight="0" leftmargin="0" topmargin="0" align="right" border="0" cellpadding="0" cellspacing="0"> <tbody><tr> <td nowrap="nowrap" valign="top"> <table topmargin="0" leftmargin="0" marginheight="0" marginwidth="0" width="140" border="0" cellpadding="0" cellspacing="0"> <tbody><tr> <td rowspan="2" width="1" align="left" bgcolor="#ffffff">
spacer.gif
</td><td rowspan="2" width="1" align="left" bgcolor="#b1bdbf">
spacer.gif
</td> <td width="138" align="left"> <table valign="top" topmargin="0" leftmargin="0" marginheight="0" marginwidth="0" width="138" align="right" bgcolor="#ffffff" border="0" cellpadding="1" cellspacing="0"> <tbody><tr><td colspan="2" bgcolor="#b1bdbf" height="20" valign="middle">[FONT=verdana,arial,helvetica,sans-serif] Jump to Section[/FONT]</td></tr> <tr><td width="5" valign="TOP"><nobr> •</nobr></td><td valign="top">[FONT=verdana,arial,helvetica,sans-serif]Top[/FONT]</td></tr> <tr><td width="5" valign="TOP"><nobr> •</nobr></td><td valign="top">[FONT=verdana,arial,helvetica,sans-serif]Introduction[/FONT]</td></tr> <tr><td width="5" valign="TOP"><nobr> •</nobr></td><td valign="top">[FONT=verdana,arial,helvetica,sans-serif]Methods[/FONT]</td></tr> <tr><td width="5" valign="TOP"><nobr> •</nobr></td><td valign="top">[FONT=verdana,arial,helvetica,sans-serif]Results[/FONT]</td></tr> <tr><td width="5" valign="TOP"><nobr> •</nobr></td><td valign="top">[FONT=verdana,arial,helvetica,sans-serif]Comment[/FONT]</td></tr> <tr><td width="5" valign="TOP"><nobr> •</nobr></td><td valign="top">[FONT=verdana,arial,helvetica,sans-serif]Author information[/FONT]</td></tr> <tr><td width="5" valign="TOP"><nobr> •</nobr></td><td valign="top">[FONT=verdana,arial,helvetica,sans-serif]References[/FONT]</td></tr> <tr><td colspan="2" height="5">
spacer.gif
</td></tr> </tbody></table></td><td rowspan="2" width="1" align="right" bgcolor="#b1bdbf">
spacer.gif
</td> </tr><tr><td width="138" bgcolor="#b1bdbf" height="1">
spacer.gif
</td> </tr></tbody></table></td></tr></tbody></table> [FONT=verdana, arial, helvetica, sans-serif]
Corresponding Author: Robert Fowler, MD, MS(Epi), Sunnybrook<sup> </sup>Health Sciences Center, 2075 Bayview Ave D478, Toronto, ON M5N<sup> </sup>3M5, Canada (rob.fowler@sunnybrook.ca<script type="text/javascript"><!-- var u = "rob.fowler", d = "sunnybrook.ca"; document.getElementById("em0").innerHTML = '<a href="mailto:' + u + '@' + d + '">' + u + '@' + d + '<\/a>'//--></script>).<sup> </sup>[/FONT]
[FONT=verdana, arial, helvetica, sans-serif]Published Online: October 12, 2009 (doi:10.1001/jama.2009.1536).<sup> </sup>[/FONT]
[FONT=verdana, arial, helvetica, sans-serif]Author Contributions: Drs Dominguez-Cherit and Fowler had full<sup> </sup>access to all of the data in the study and take responsibility<sup> </sup>for the integrity of the data and the accuracy of the data analysis.<sup> </sup>[/FONT]
[FONT=verdana, arial, helvetica, sans-serif]Study concept and design: Domínguez-Cherit, Lapinsky,<sup> </sup>Stewart, Fowler.<sup> </sup>[/FONT]
[FONT=verdana, arial, helvetica, sans-serif]Acquisition of data: Domínguez-Cherit, Macias, Espinosa-Perez,<sup> </sup>de la Torre, Poblano-Morales, Baltazar-Torres, Bautista, A.<sup> </sup>Martinez, M. Martinez, Rivero, Valdez, Ruiz-Palacios, Hernández,<sup> </sup>Fowler.<sup> </sup>[/FONT]
[FONT=verdana, arial, helvetica, sans-serif]Analysis and interpretation of data: Domínguez-Cherit,<sup> </sup>Lapinsky, Espinosa-Perez, Pinto, Stewart, Fowler.<sup> </sup>[/FONT]
[FONT=verdana, arial, helvetica, sans-serif]Drafting of the manuscript: Domínguez-Cherit, Lapinsky,<sup> </sup>Macias, Pinto, Espinosa-Perez, de la Torre, Poblano-Morales,<sup> </sup>Baltazar-Torres, Bautista, A. Martinez, M. Martinez, Rivero,<sup> </sup>Valdez, Ruiz-Palacios, Hernández, Stewart, Fowler.<sup> </sup>[/FONT]
[FONT=verdana, arial, helvetica, sans-serif]Critical revision of the manuscript for important intellectual<sup> </sup>content: Domínguez-Cherit, Macias, Espinosa-Perez, de<sup> </sup>la Torre, Ruiz-Palacios, Stewart, Fowler.<sup> </sup>[/FONT]
[FONT=verdana, arial, helvetica, sans-serif]Statistical analysis: Pinto, Fowler.<sup> </sup>[/FONT]
[FONT=verdana, arial, helvetica, sans-serif]Administrative, technical, or material support: Domínguez-Cherit,<sup> </sup>Lapinsky, Espinosa-Perez, Baltazar-Torres, Stewart, Fowler.<sup> </sup>[/FONT]
[FONT=verdana, arial, helvetica, sans-serif]Study supervision: Domínguez-Cherit, Stewart, Fowler.<sup> </sup>[/FONT]
[FONT=verdana, arial, helvetica, sans-serif]Financial Disclosures: None reported.<sup> </sup>[/FONT]
[FONT=verdana, arial, helvetica, sans-serif]Participating Centers: Instituto Nacional de Ciencias Médicas<sup> </sup>y Nutrición "Salvador Zubirán," México<sup> </sup>City, México; Hospital General "Dr. Manuel Gea Gonzalez,"<sup> </sup>México City; School of Medicine Instituto Tecnologico<sup> </sup>de Monterrey, Monterrey City, México; Hospital Juarez<sup> </sup>de Mexico, México City; Hospital San Jose-Tec de Monterrey,<sup> </sup>Monterrey City, México; Instituto Nacional de Enfermedades<sup> </sup>Respiratorias, México City; Instituto Nacional de Diagnóstico<sup> </sup>y Referencia Epidemiológicos, México City.<sup> </sup>[/FONT]
[FONT=verdana, arial, helvetica, sans-serif]Previous Presentations: Presented in part at the International<sup> </sup>Conference of the American Thoracic Society; May 20, 2009; San<sup> </sup>Diego, California.<sup> </sup>[/FONT]
[FONT=verdana, arial, helvetica, sans-serif]Additional Contributions: We thank the following persons for<sup> </sup>providing input on the study design and conduct: Mexico: Instituto<sup> </sup>Nacional de Ciencias Medicas y Nutrición "Salvador Zubiran":<sup> </sup>Delia Borunda-Nava, MD, Carlos Rodriguez-Osorio, MD, Silvio<sup> </sup>Antonio Ñamendys, MD, MSc, Antonio Fonseca, MD, Guadalupe<sup> </sup>Morales, RN, Martha Huertas, RN; Patricia Leal, MD, Arturo Galindo<sup> </sup>Fraga, MD, Rafael Franco, MD, Sarbelio Moreno-Espinosa, MD,<sup> </sup>MSc; Hospital General "Dr Manuel Gea Gonzalez" Influenza Committee:<sup> </sup>Simon Kawa Karasik, MD, Araceli Contreras Molina, RN, Rafael<sup> </sup>Figueroa Moreno, MD, Jose Jesús Acevedo Mariles, MD,<sup> </sup>Carlos Alberto San Juan Martínez, MD, Guillermo Bierzwinsky<sup> </sup>Sneider, MD, Laura Ramírez Preciado, MD, Alejandro Avalos<sup> </sup>Bracho, MD, Lucina Gutierrez Sánchez, RN, Antonio Martínez<sup> </sup>Conde, MD, Antonio Lavalle Villalobos, MD, Lorena Hernández<sup> </sup>Delgado, MD, Gerardo Lara Figueroa, MD, Hector Prado Calleros,<sup> </sup>MD, Jeremy Farrar, MD, Alejandro Flores (emergency room technician);<sup> </sup>Hospital de Especialidades CMN la Raza IMSS: Alejandro Sanchez<sup> </sup>Hurtado, MD, Claudia Lopez Nava, MD; Hospital Juarez de México:<sup> </sup>Jose M. Conde-Mercado, MD, Monica Cureño-Diaz, MD, Ariel<sup> </sup>Estrada-Aguilera, MD, Claudia Vazquez-Zamora, MD, Mayte Martinez-Velazquez,<sup> </sup>MD, David Hernandez-Lopez, MD; Hospital San Jose Tec de Monterrey:<sup> </sup>Javier Valero Gomez, MD, Carlos Diaz Olachea, MD, Estrella Gonzalez,<sup> </sup>MD; School of Medicine Tecnologico de Monterrey: Rocio Cabrera<sup> </sup>(bioengineer); and all the Intensive Care Unit and Medical Intensive<sup> </sup>Care Unit nurse staff for all the effort and devotion of their<sup> </sup>work at the Inistituto Nacional de Enferemedades Respiratorias.<sup> </sup>Canada and United States: John Marshall, MD, Arthur Slutsky,<sup> </sup>MD, Phil Hebert, MD, PhD, Blair Henry, MSc, Francois Lamontagne,<sup> </sup>MD, Gordon Rubenfeld, MD, MSc, Andy Simor, MD, Muhammad Mamdani,<sup> </sup>PharmD, MA, MPH, Judith Hall, MSc, Bryan Boodhoo, and the Li<sup> </sup>Ka Shing Knowledge Institute of St. Michael's Hospital; Neill<sup> </sup>Adhikari, MDCM, MSc, Damon Scales, MD, PhD, Richard Mraz, PEng,<sup> </sup>Barry McLellan, MD, Karen Choong, MD, Kusem Menon, MD, MSc,<sup> </sup>Dominique Piquette, MD, MSc, Michael Christian, MD, Jeff Singh,<sup> </sup>MD, MSc, Orla Smith, MSc, Ellen McDonald, RN, Claudio Martin,<sup> </sup>MD, MSc, Francois Lellouche, MD, Nicole Zytaruk, RN, Lauralyn<sup> </sup>McIntyre, MD, MSc, Tom Stelfox, MD, PHD, John Granton, MD, Anand<sup> </sup>Kumar, MD, Ryan Zarychanski, MD, MSc, David Wensley, MD, Dermot<sup> </sup>Doherty, MD, Sandra Dial, MD, Sean Keenan, MD, MSc, Sheldon<sup> </sup>Magder, MD, David Hornstein, MD, David Leasa, MD, Rick Hall,<sup> </sup>MD, Mark Crowther, MD, MSc, Donald Griesdale, MD, Jamie Hutchison,<sup> </sup>MD, Jan Friedrich, MD, DPhil, Nial Ferguson, MD, MSc, Jacques<sup> </sup>Lacroix, MD, Peter Dodek, MD, MHSc, Philippe Jouvet, MD, PhD,<sup> </sup>Steve Webb, MD, Simon Finfer, MD, Jamie Cooper, MD, Allison<sup> </sup>McGeer, MD, Tex Kissoon, MD, Brian Cuthbertson, MB, ChB, Cathy<sup> </sup>Tansey, PhD, Ari Joffe, MD, Craig Coopersmith, MD, the American<sup> </sup>Thoracic Society, the Society of Critical Care Medicine, the<sup> </sup>University of Toronto Interdepartmental Division of Critical<sup> </sup>Care Medicine, and the Canadian Critical Care Trials Group.<sup> </sup>[/FONT]
<!--stopindex--> <!--null-->[FONT=verdana, arial, helvetica, sans-serif] Author Affiliations: Division of Pulmonary and Critical Care (Dr Domínguez-Cherit), Hospital Epidemiology Department (Drs de la Torre and Macias), Infectious Disease Department (Dr Ruiz-Palacios), and Department of Critical Care Medicine (Dr Rivero), Instituto Nacional de Ciencias Médicas y Nutrición "Salvador Zubirán," México City, México; Interdepartmental Division of Critical Care Medicine and Department of Medicine, University of Toronto and Mount Sinai Hospital, Toronto, Ontario, Canada (Dr Lapinsky); School of Medicine, Instituto Tecnologico de Estudios Superiores de Monterrey, Monterrey, México (Dr Espinosa-Perez); Interdepartmental Division of Critical Care Medicine and Department of Medicine, University of Toronto and Sunnybrook Health Sciences Centre, Toronto (Dr Pinto); Hospital Juarez de México, México City (Dr Poblano-Morales); Hospital de Especialidades Centro Medico La Raza, IMSS, México City (Dr Baltazar-Torres); Instituto Nacional de Enfermedades Respiratorias, México City (Dr Bautista); Department of Internal Medicine (Drs A. Martinez and M. A. Martinez) and Infectious Disease Hospital (Dr Valdez), Hospital General "Dr. Manuel Gea Gonzalez," México City; Hospital San Jose-Tec de Monterrey, Monterrey City (Dr Hernández); Interdepartmental Division of Critical Care Medicine and Department of Medicine and Anaesthesia, University of Toronto, Mount Sinai Hospital, University Health Network, Toronto (Dr Stewart); and Interdepartmental Division of Critical Care Medicine and Department of Medicine, University of Toronto and Sunnybrook Health Sciences Centre, Toronto (Dr Fowler). [/FONT]
<!-- null -->
[FONT=verdana, arial, helvetica, sans-serif] REFERENCES [/FONT] <table width="100%" border="0" cellpadding="0" cellspacing="0"> <tbody><tr> <td width="100%" bgcolor="#6a90aa">
spacer.gif
</td><td>
spacer.gif
</td></tr></tbody></table> <table marginwidth="0" marginheight="0" leftmargin="0" topmargin="0" align="right" border="0" cellpadding="0" cellspacing="0"> <tbody><tr> <td nowrap="nowrap" valign="top"> <table topmargin="0" leftmargin="0" marginheight="0" marginwidth="0" width="140" border="0" cellpadding="0" cellspacing="0"> <tbody><tr> <td rowspan="2" width="1" align="left" bgcolor="#ffffff">
spacer.gif
</td><td rowspan="2" width="1" align="left" bgcolor="#b1bdbf">
spacer.gif
</td> <td width="138" align="left"> <table valign="top" topmargin="0" leftmargin="0" marginheight="0" marginwidth="0" width="138" align="right" bgcolor="#ffffff" border="0" cellpadding="1" cellspacing="0"> <tbody><tr><td colspan="2" bgcolor="#b1bdbf" height="20" valign="middle">[FONT=verdana,arial,helvetica,sans-serif] Jump to Section[/FONT]</td></tr> <tr><td width="5" valign="TOP"><nobr> •</nobr></td><td valign="top">[FONT=verdana,arial,helvetica,sans-serif]Top[/FONT]</td></tr> <tr><td width="5" valign="TOP"><nobr> •</nobr></td><td valign="top">[FONT=verdana,arial,helvetica,sans-serif]Introduction[/FONT]</td></tr> <tr><td width="5" valign="TOP"><nobr> •</nobr></td><td valign="top">[FONT=verdana,arial,helvetica,sans-serif]Methods[/FONT]</td></tr> <tr><td width="5" valign="TOP"><nobr> •</nobr></td><td valign="top">[FONT=verdana,arial,helvetica,sans-serif]Results[/FONT]</td></tr> <tr><td width="5" valign="TOP"><nobr> •</nobr></td><td valign="top">[FONT=verdana,arial,helvetica,sans-serif]Comment[/FONT]</td></tr> <tr><td width="5" valign="TOP"><nobr> •</nobr></td><td valign="top">[FONT=verdana,arial,helvetica,sans-serif]Author information[/FONT]</td></tr> <tr><td width="5" valign="TOP"><nobr> •</nobr></td><td valign="top">[FONT=verdana,arial,helvetica,sans-serif]References[/FONT]</td></tr> <tr><td colspan="2" height="5">
spacer.gif
</td></tr> </tbody></table></td><td rowspan="2" width="1" align="right" bgcolor="#b1bdbf">
spacer.gif
</td> </tr><tr><td width="138" bgcolor="#b1bdbf" height="1">
spacer.gif
</td> </tr></tbody></table></td></tr></tbody></table> [FONT=verdana, arial, helvetica, sans-serif]
[FONT=verdana, arial, helvetica, sans-serif] <!-- null -->1. Centers for Disease Control and Prevention. Swine influenza A (H1N1) infection in two children—Southern California, March-April 2009. MMWR Morb Mortal Wkly Rep. 2009;58(15):400-402.<!-- HIGHWIRE ID="0:2009:2009.1536:1" --> [FONT=verdana, arial, helvetica, sans-serif]PUBMED[/FONT] <!-- /HIGHWIRE --><table width="100%" border="0" cellpadding="0" cellspacing="0"><tbody><tr><td>
spacer.gif
</td></tr></tbody></table><!-- null -->2. Global Alert and Response (GAR)—Pandemic (H1N1) 2009. World Health Organization Web site. http://www.who.int/csr/disease/swineflu/en. Accessed September 9, 2009.<!-- HIGHWIRE ID="0:2009:2009.1536:2" --><!-- /HIGHWIRE --><table width="100%" border="0" cellpadding="0" cellspacing="0"><tbody><tr><td>
spacer.gif
</td></tr></tbody></table><!-- null -->3. Global Alert and Response (GAR)—Influenza-like illness in the United States and Mexico. World Health Organization Web site. http://www.who.int/csr/don/2009_04_24/en/index.html. Accessed May 8, 2009.<!-- HIGHWIRE ID="0:2009:2009.1536:3" --><!-- /HIGHWIRE --><table width="100%" border="0" cellpadding="0" cellspacing="0"><tbody><tr><td>
spacer.gif
</td></tr></tbody></table><!-- null -->4. Centers for Disease Control and Prevention (CDC). Novel influenza A (H1N1) virus infections—worldwide, May 6, 2009. MMWR Morb Mortal Wkly Rep. 2009;58(17):453-458.<!-- HIGHWIRE ID="0:2009:2009.1536:4" --> [FONT=verdana, arial, helvetica, sans-serif]PUBMED[/FONT] <!-- /HIGHWIRE --><table width="100%" border="0" cellpadding="0" cellspacing="0"><tbody><tr><td>
spacer.gif
</td></tr></tbody></table><!-- null -->5. Gráficas defunciones: descripción preliminar. Mexico Secretaria de Salud Web site. http://portal.salud.gob.mx/contenidos/noticias/influenza/estadisticas.html. Accessed May 8, 2009.<!-- HIGHWIRE ID="0:2009:2009.1536:5" --><!-- /HIGHWIRE --><table width="100%" border="0" cellpadding="0" cellspacing="0"><tbody><tr><td>
spacer.gif
</td></tr></tbody></table><!-- null -->6. Situación actual de la epidemia. Mexico Secretaria de Salud Web site. http://portal.salud.gob.mx/sites/salud/descargas/pdf/influenza/presentacion20090505.pdf. Accessed May 8, 2009.<!-- HIGHWIRE ID="0:2009:2009.1536:6" --><!-- /HIGHWIRE --><table width="100%" border="0" cellpadding="0" cellspacing="0"><tbody><tr><td>
spacer.gif
</td></tr></tbody></table><!-- null -->7. Dawood FS, Jain S, Finelli L; et al, Novel Swine-Origin Influenza A(H1N1) Virus Investigation Team. Emergence of a novel swine-origin influenza A (H1N1) virus in humans. N Engl J Med. 2009;360(25):2605-2615.<!-- HIGHWIRE ID="0:2009:2009.1536:7" --> [FONT=verdana, arial, helvetica, sans-serif]<nobr>FREE FULL TEXT</nobr>[/FONT] <!-- /HIGHWIRE --><table width="100%" border="0" cellpadding="0" cellspacing="0"><tbody><tr><td>
spacer.gif
</td></tr></tbody></table><!-- null -->8. Global Alert and Response (GAR)—Pandemic (H1N1) guidance documents. World Health Organization Web site. http://www.who.int/csr/resources/publications/swineflu/en/. Accessed May 31, 2009.<!-- HIGHWIRE ID="0:2009:2009.1536:8" --><!-- /HIGHWIRE --><table width="100%" border="0" cellpadding="0" cellspacing="0"><tbody><tr><td>
spacer.gif
</td></tr></tbody></table><!-- null -->9. Interim guidance on case definitions to be used for investigations of novel influenza A (H1N1) cases. Centers for Disease Control and Prevention Web site. http://www.cdc.gov/h1n1flu/casedef.htm. Accessed May 31, 2009.<!-- HIGHWIRE ID="0:2009:2009.1536:9" --><!-- /HIGHWIRE --><table width="100%" border="0" cellpadding="0" cellspacing="0"><tbody><tr><td>
spacer.gif
</td></tr></tbody></table><!-- null -->10. Case definitions for national surveillance H1N1 flu virus. Public Health Agency of Canada Web site. http://www.phac-aspc.gc.ca/alert-alerte/swine-porcine/hp-ps-info_definition-eng.php. Accessed May 31, 2009.<!-- HIGHWIRE ID="0:2009:2009.1536:10" --><!-- /HIGHWIRE --><table width="100%" border="0" cellpadding="0" cellspacing="0"><tbody><tr><td>
spacer.gif
</td></tr></tbody></table><!-- null -->11. Influenza related research initiative. Canadian Critical Care Trials Group Web site. http://www.ccctg.ca/news_events.php. Accessed May 31, 2009.<!-- HIGHWIRE ID="0:2009:2009.1536:11" --><!-- /HIGHWIRE --><table width="100%" border="0" cellpadding="0" cellspacing="0"><tbody><tr><td>
spacer.gif
</td></tr></tbody></table><!-- null -->12. Society of Critical Care Medicine H1N1 Influenza ICU Study. Canadian Critical Care Trials Group Web site. http://www.ccctg.ca/index.php. Accessed May 31, 2009.<!-- HIGHWIRE ID="0:2009:2009.1536:12" --><!-- /HIGHWIRE --><table width="100%" border="0" cellpadding="0" cellspacing="0"><tbody><tr><td>
spacer.gif
</td></tr></tbody></table><!-- null -->13. Late breaking session on influenza A (H1N1). Presented at: American Thoracic Society 2009 International Conference; May 15-20, 2009; San Diego, CA. American Thoracic Society Web site. http://psavcms-sales.com/ats2009/h1n1.html. Accessed May 31, 2009.<!-- HIGHWIRE ID="0:2009:2009.1536:13" --><!-- /HIGHWIRE --><table width="100%" border="0" cellpadding="0" cellspacing="0"><tbody><tr><td>
spacer.gif
</td></tr></tbody></table><!-- null -->14. University of Toronto Interdepartmental Division of Critical Care Web site. http://www.criticalcare.utoronto.ca/site3.aspx. Accessed May 31, 2009.<!-- HIGHWIRE ID="0:2009:2009.1536:14" --><!-- /HIGHWIRE --><table width="100%" border="0" cellpadding="0" cellspacing="0"><tbody><tr><td>
spacer.gif
</td></tr></tbody></table><!-- null -->15. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med. 1985;13(10):818-829.<!-- HIGHWIRE ID="0:2009:2009.1536:15" --> [FONT=verdana, arial, helvetica, sans-serif]PUBMED[/FONT] <!-- /HIGHWIRE --><table width="100%" border="0" cellpadding="0" cellspacing="0"><tbody><tr><td>
spacer.gif
</td></tr></tbody></table><!-- null -->16. Pollack MM, Patel KM, Ruttimann UE. PRISM III: an updated Pediatric Risk of Mortality score. Crit Care Med. 1996;24(5):743-752.<!-- HIGHWIRE ID="0:2009:2009.1536:16" --> [FONT=verdana, arial, helvetica, sans-serif]PUBMED[/FONT] <!-- /HIGHWIRE --><table width="100%" border="0" cellpadding="0" cellspacing="0"><tbody><tr><td>
spacer.gif
</td></tr></tbody></table><!-- null -->17. Vincent JL, Moreno R, Takala J; et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. Intensive Care Med. 1996;22(7):707-710.<!-- HIGHWIRE ID="0:2009:2009.1536:17" --> [FONT=verdana, arial, helvetica, sans-serif]PUBMED[/FONT] <!-- /HIGHWIRE --><table width="100%" border="0" cellpadding="0" cellspacing="0"><tbody><tr><td>
spacer.gif
</td></tr></tbody></table><!-- null -->18. Influenza A (H1N1)—update 32. World Health Organization Web site. June 1, 2009. http://www.who.int/csr/don/2009_06_01a/en/index.html. Accessed September 9, 2009.<!-- HIGHWIRE ID="0:2009:2009.1536:18" --><!-- /HIGHWIRE --><table width="100%" border="0" cellpadding="0" cellspacing="0"><tbody><tr><td>
spacer.gif
</td></tr></tbody></table><!-- null -->19. Martínez-Guerra ML, Fernández Bonetti P, Balvanera Abreu A, Correa R, Elizalde Ramos A, Soní Cassani J. Normal values of various measures of respiratory function in Mexico City [in Spanish]. Prensa Med Mex. 1973;38(1):1-5.<!-- HIGHWIRE ID="0:2009:2009.1536:19" --> [FONT=verdana, arial, helvetica, sans-serif]PUBMED[/FONT] <!-- /HIGHWIRE --><table width="100%" border="0" cellpadding="0" cellspacing="0"><tbody><tr><td>
spacer.gif
</td></tr></tbody></table><!-- null -->20. Phua J, Badia JR, Adhikari NK; et al. Has mortality from acute respiratory distress syndrome decreased over time? a systematic review. Am J Respir Crit Care Med. 2009;179(3):220-227.<!-- HIGHWIRE ID="0:2009:2009.1536:20" --> [FONT=verdana, arial, helvetica, sans-serif]<nobr>FREE FULL TEXT</nobr>[/FONT] <!-- /HIGHWIRE --><table width="100%" border="0" cellpadding="0" cellspacing="0"><tbody><tr><td>
spacer.gif
</td></tr></tbody></table><!-- null -->21. Oliveira EC, Lee B, Colice GL. Influenza in the intensive care unit. J Intensive Care Med. 2003;18(2):80-91.<!-- HIGHWIRE ID="0:2009:2009.1536:21" --> [FONT=verdana, arial, helvetica, sans-serif]<nobr>FREE FULL TEXT</nobr>[/FONT] <!-- /HIGHWIRE --><table width="100%" border="0" cellpadding="0" cellspacing="0"><tbody><tr><td>
spacer.gif
</td></tr></tbody></table><!-- null -->22. Fowler RA, Lapinsky SE, Hallett D; et al, Toronto SARS Critical Care Group. Critically ill patients with severe acute respiratory syndrome. JAMA. 2003;290(3):367-373.<!-- HIGHWIRE ID="0:2009:2009.1536:22" --> [FONT=verdana, arial, helvetica, sans-serif]<nobr>FREE FULL TEXT</nobr>[/FONT] <!-- /HIGHWIRE --><table width="100%" border="0" cellpadding="0" cellspacing="0"><tbody><tr><td>
spacer.gif
</td></tr></tbody></table><!-- null -->23. Centers for Disease Control and Prevention (CDC). Serum cross-reactive antibody response to a novel influenza A (H1N1) virus after vaccination with seasonal influenza vaccine. MMWR Morb Mortal Wkly Rep. 2009;58(19):521-524.<!-- HIGHWIRE ID="0:2009:2009.1536:23" --> [FONT=verdana, arial, helvetica, sans-serif]PUBMED[/FONT] <!-- /HIGHWIRE --><table width="100%" border="0" cellpadding="0" cellspacing="0"><tbody><tr><td>
spacer.gif
</td></tr></tbody></table><!-- null -->24. The World Factbook: field listing: age structure. Central Intelligence Agency Web site. https://www.cia.gov/library/publications/the-world-factbook/fields/2010.html. Accessed June 6, 2009.<!-- HIGHWIRE ID="0:2009:2009.1536:24" --><!-- /HIGHWIRE --><table width="100%" border="0" cellpadding="0" cellspacing="0"><tbody><tr><td>
spacer.gif
</td></tr></tbody></table><!-- null -->25. Carrat F, Vergu E, Ferguson NM; et al. Time lines of infection and disease in human influenza: a review of volunteer challenge studies. Am J Epidemiol. 2008;167(7):775-785.<!-- HIGHWIRE ID="0:2009:2009.1536:25" --> [FONT=verdana, arial, helvetica, sans-serif]<nobr>FREE FULL TEXT</nobr>[/FONT] <!-- /HIGHWIRE --><table width="100%" border="0" cellpadding="0" cellspacing="0"><tbody><tr><td>
spacer.gif
</td></tr></tbody></table><!-- null -->26. Gruber PC, Gomersall CD, Joynt GM. Avian influenza (H5N1): implications for intensive care. Intensive Care Med. 2006;32(6):823-829.<!-- HIGHWIRE ID="0:2009:2009.1536:26" --> [FONT=verdana, arial, helvetica, sans-serif]PUBMED[/FONT] <!-- /HIGHWIRE --><table width="100%" border="0" cellpadding="0" cellspacing="0"><tbody><tr><td>
spacer.gif
</td></tr></tbody></table><!-- null -->27. Arabi Y, Gomersall CD, Ahmed QA, Boynton BR, Memish ZA. The critically ill avian influenza A (H5N1) patient. Crit Care Med. 2007;35(5):1397-1403.<!-- HIGHWIRE ID="0:2009:2009.1536:27" --> [FONT=verdana, arial, helvetica, sans-serif]PUBMED[/FONT] <!-- /HIGHWIRE --><table width="100%" border="0" cellpadding="0" cellspacing="0"><tbody><tr><td>
spacer.gif
</td></tr></tbody></table><!-- null -->28. Li FC, Choi BC, Sly T, Pak AW. Finding the real case-fatality rate of H5N1 avian influenza. J Epidemiol Community Health. 2008;62(6):555-559.<!-- HIGHWIRE ID="0:2009:2009.1536:28" --> [FONT=verdana, arial, helvetica, sans-serif]<nobr>FREE FULL TEXT</nobr>[/FONT] <!-- /HIGHWIRE --><table width="100%" border="0" cellpadding="0" cellspacing="0"><tbody><tr><td>
spacer.gif
</td></tr></tbody></table><!-- null -->29. Morens DM, Fauci AS. The 1918 influenza pandemic: insights from the 21st century. J Infect Dis. 2007;195(7):1018-1028.<!-- HIGHWIRE ID="0:2009:2009.1536:29" --> [FONT=verdana, arial, helvetica, sans-serif]PUBMED[/FONT] <!-- /HIGHWIRE --><table width="100%" border="0" cellpadding="0" cellspacing="0"><tbody><tr><td>
spacer.gif
</td></tr></tbody></table><!-- null -->30. Abe M, Higuchi T, Okada K, Kaizu K, Matsumoto K. Clinical study of influenza-associated rhabdomyolysis with acute renal failure. Clin Nephrol. 2006;66(3):166-170.<!-- HIGHWIRE ID="0:2009:2009.1536:30" --> [FONT=verdana, arial, helvetica, sans-serif]PUBMED[/FONT] <!-- /HIGHWIRE --><table width="100%" border="0" cellpadding="0" cellspacing="0"><tbody><tr><td>
spacer.gif
</td></tr></tbody></table><!-- null -->31. Simon NM, Rovner RN, Berlin BS. Acute myoglobinuria associated with type A2 (Hong Kong) influenza. JAMA. 1970;212(10):1704-1705.<!-- HIGHWIRE ID="0:2009:2009.1536:31" --> [FONT=verdana, arial, helvetica, sans-serif]<nobr>FREE FULL TEXT</nobr>[/FONT] <!-- /HIGHWIRE --><table width="100%" border="0" cellpadding="0" cellspacing="0"><tbody><tr><td>
spacer.gif
</td></tr></tbody></table><!-- null -->32. WHO Global Infobase: BMI/overweight/obesity. World Health Organization Web site. https://apps.who.int/infobase/compa...year=2005&sf1=cd.0701&sex=all&agegroup=15-100. Accessed September 10, 2009.<!-- HIGHWIRE ID="0:2009:2009.1536:32" --><!-- /HIGHWIRE --><table width="100%" border="0" cellpadding="0" cellspacing="0"><tbody><tr><td>
spacer.gif
</td></tr></tbody></table><!-- null -->33. O’Brien JM Jr, Phillips GS, Ali NA, Lucarelli M, Marsh CB, Lemeshow S. Body mass index is independently associated with hospital morbidity and mortality in mechanically ventilated adults with acute lung injury. Crit Care Med. 2006;34(3):738-744.<!-- HIGHWIRE ID="0:2009:2009.1536:33" --> [FONT=verdana, arial, helvetica, sans-serif]PUBMED[/FONT] <!-- /HIGHWIRE --><table width="100%" border="0" cellpadding="0" cellspacing="0"><tbody><tr><td>
spacer.gif
</td></tr></tbody></table><!-- null -->34. Christian MD, Hawryluck L, Wax RS; et al. Development of a triage protocol for critical care during an influenza pandemic. CMAJ. 2006;175(11):1377-1381.<!-- HIGHWIRE ID="0:2009:2009.1536:34" --> [FONT=verdana, arial, helvetica, sans-serif]<nobr>FREE FULL TEXT</nobr>[/FONT] <!-- /HIGHWIRE --><table width="100%" border="0" cellpadding="0" cellspacing="0"><tbody><tr><td>
spacer.gif
</td></tr></tbody></table><!-- null -->35. Fraser C, Donnelly CA, Cauchemez W; et al, WHO Rapid Pandemic Assessment Collaboration. Pandemic potential of a strain of influenza A (H1N1): early findings [published online ahead of print May 11, 2009]. Science. doi:10.1126/science.1176062. 2009;324(5934):1557-1561.<!-- HIGHWIRE ID="0:2009:2009.1536:35" --> [FONT=verdana, arial, helvetica, sans-serif]<nobr>FREE FULL TEXT</nobr>[/FONT] <!-- /HIGHWIRE --><table width="100%" border="0" cellpadding="0" cellspacing="0"><tbody><tr><td>
spacer.gif
</td></tr></tbody></table><!-- null -->36. Kerr JR. Swine influenza [published online ahead of print May 10, 2009]. J Clin Pathol. doi:10.1136/jcp.2009.067710. 2009;62(7):577-578.<!-- HIGHWIRE ID="0:2009:2009.1536:36" --> [FONT=verdana, arial, helvetica, sans-serif]FREE FULL TEXT[/FONT] <!-- /HIGHWIRE --><table width="100%" border="0" cellpadding="0" cellspacing="0"><tbody><tr><td>
spacer.gif
</td></tr></tbody></table>[/FONT] [/FONT]
[FONT=verdana, arial, helvetica, sans-serif][FONT=verdana, arial, helvetica, sans-serif] Caring for the Critically Ill Patient Section Editor: Derek C. Angus, MD, MPH, Contributing Editor, JAMA (angusdc@upmc.edu<script type="text/javascript"><!-- var u = "angusdc", d = "upmc.edu"; document.getElementById("em1").innerHTML = '<a href="mailto:' + u + '@' + d + '">' + u + '@' + d + '<\/a>'//--></script>).[/FONT][/FONT]
[FONT=verdana, arial, helvetica, sans-serif]

[FONT=verdana,arial,helvetica,sans-serif] CiteULike Connotea Del.icio.us Digg Reddit Technorati Twitter [/FONT] [FONT=verdana,arial,helvetica,sans-serif]What's this?[/FONT]
[/FONT]
[FONT=verdana, arial, helvetica, sans-serif][FONT=verdana,arial,helvetica,sans-serif] <!-- null --> [FONT=verdana,arial,helvetica,sans-serif]RELATED ARTICLES[/FONT] <table width="100%" border="0" cellpadding="0" cellspacing="0"><tbody><tr><td width="100%" bgcolor="#6a90aa">
spacer.gif
</td></tr></tbody></table> [/FONT][/FONT]
[FONT=verdana, arial, helvetica, sans-serif][FONT=verdana,arial,helvetica,sans-serif] Critically Ill Patients With 2009 Influenza A(H1N1) Infection in Canada
Anand Kumar, Ryan Zarychanski, Ruxandra Pinto, Deborah J. Cook, John Marshall, Jacques Lacroix, Tom Stelfox, Sean Bagshaw, Karen Choong, Francois Lamontagne, Alexis F. Turgeon, Stephen Lapinsky, Stéphane P. Ahern, Orla Smith, Faisal Siddiqui, Philippe Jouvet, Kosar Khwaja, Lauralyn McIntyre, Kusum Menon, Jamie Hutchison, David Hornstein, Ari Joffe, Francois Lauzier, Jeffrey Singh, Tim Karachi, Kim Wiebe, Kendiss Olafson, Clare Ramsey, Satendra Sharma, Peter Dodek, Maureen Meade, Richard Hall, Robert Fowler, and for the Canadian Critical Care Trials Group H1N1 Collaborative
JAMA. 2009;0(2009):20091496-8.
<nobr> ABSTRACT | FULL TEXT </nobr> [/FONT][/FONT]
[FONT=verdana, arial, helvetica, sans-serif][FONT=verdana,arial,helvetica,sans-serif] Extracorporeal Membrane Oxygenation for 2009 Influenza A(H1N1) Acute Respiratory Distress Syndrome
The Australia and New Zealand Extracorporeal Membrane Oxygenation (ANZ ECMO) Influenza Investigators
JAMA. 2009;0(2009):20091535-8.
<nobr> ABSTRACT | FULL TEXT </nobr> [/FONT][/FONT]
[FONT=verdana, arial, helvetica, sans-serif][FONT=verdana,arial,helvetica,sans-serif] Preparing for the Sickest Patients With 2009 Influenza A(H1N1)
Douglas B. White and Derek C. Angus
JAMA. 2009;0(2009):20091539-2.
<nobr> EXTRACT | FULL TEXT </nobr> [/FONT][/FONT]
[FONT=verdana, arial, helvetica, sans-serif][FONT=verdana,arial,helvetica,sans-serif]
[/FONT][/FONT]

[FONT=verdana, arial, helvetica, sans-serif][FONT=verdana,arial,helvetica,sans-serif]<!-- null --> [/FONT][/FONT]
[FONT=verdana, arial, helvetica, sans-serif][FONT=verdana,arial,helvetica,sans-serif][FONT=verdana,arial,helvetica,sans-serif]THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES[/FONT] <table width="100%" border="0" cellpadding="0" cellspacing="0"><tbody><tr><td width="100%" bgcolor="#6a90aa">
spacer.gif
</td></tr></tbody></table> [/FONT][/FONT]
[FONT=verdana, arial, helvetica, sans-serif][FONT=verdana,arial,helvetica,sans-serif][FONT=verdana,arial,helvetica,sans-serif] Preparing for the Sickest Patients With 2009 Influenza A(H1N1)
White and Angus
JAMA 2009;0:2009.1539-2.
<nobr> FULL TEXT </nobr> [/FONT][/FONT][/FONT]
 
Re: JAMA. Critically Ill Patients With 2009 Influenza A(H1N1) in Mexico

" Novel findings include possible worse outcomes among patients presenting with an elevated creatine kinase level."


Creatine kinase is often determined routinely in emergency patients. In addition, it is determined specifically in patients with chest pain and acute renal failure is suspected. Normal values are usually between 60 and 400 U/L,<sup id="cite_ref-4" class="reference">[5]</sup> where one unit is enzyme activity, more specifically the amount of enzyme that will catalyze 1 μmol of substrate per minute under specified conditions (temperature, pH, substrate concentrations and activators.<sup id="cite_ref-5" class="reference">[6]</sup> This test is not specific for the type of CK that is elevated.

Elevation of CK is an indication of damage to muscle. It is therefore indicative of injury, rhabdomyolysis, myocardial infarction, muscular dystrophy, myositis, myocarditis, malignant hyperthermia, and neuroleptic malignant syndrome. It is also seen in McLeod syndrome and hypothyroidism.

The use of statin medications, which are commonly used to decrease serum cholesterol levels, may be associated with elevation of the CPK level in about 1% of the patients taking these medications, and with actual muscle damage in a much smaller proportion.


http://en.wikipedia.org/wiki/Creatine_kinase
 
You must log in or register to reply here.
Back
Top Bottom